

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2025

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-38276

**APELLIS PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

100 Fifth Avenue,  
Waltham, MA  
(Address of principal executive offices)

27-1537290  
(I.R.S. Employer  
Identification No.)

02451  
(Zip Code)

Registrant's telephone number, including area code: (617) 977-5700

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	APLS	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Small reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of October 23, 2025, the registrant had 126,525,218 shares of common stock, \$0.0001 par value per share, outstanding.

---

**APELLIS PHARMACEUTICALS, INC.**  
**FORM 10-Q**  
**FOR THE QUARTER ENDED SEPTEMBER 30, 2025**

**TABLE OF CONTENTS**

	<b>Page</b>
<b><u>PART I.</u></b>	
<b><u>FINANCIAL INFORMATION</u></b>	
<u>Item 1.</u>	3
<a href="#"><u>Financial Statements (Unaudited)</u></a>	3
<a href="#"><u>Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024</u></a>	3
<a href="#"><u>Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss) for the three and nine months ended September 30, 2025 and 2024</u></a>	4
<a href="#"><u>Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024</u></a>	5
<a href="#"><u>Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024</u></a>	7
<a href="#"><u>Notes to Unaudited Condensed Consolidated Financial Statements</u></a>	8
<u>Item 2.</u>	23
<a href="#"><u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u></a>	23
<u>Item 3.</u>	36
<a href="#"><u>Quantitative and Qualitative Disclosures About Market Risk</u></a>	36
<u>Item 4.</u>	36
<a href="#"><u>Controls and Procedures</u></a>	36
<b><u>PART II.</u></b>	
<b><u>OTHER INFORMATION</u></b>	
<u>Item 1.</u>	37
<a href="#"><u>Legal Proceedings</u></a>	37
<u>Item 1A.</u>	37
<a href="#"><u>Risk Factors</u></a>	37
<u>Item 5.</u>	37
<a href="#"><u>Other Information</u></a>	37
<u>Item 6.</u>	38
<a href="#"><u>Exhibits</u></a>	38
<a href="#"><u>Signatures</u></a>	39

## Special Note Regarding Forward-Looking Statements and Industry Data

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, among other things, statements about:

- the ongoing commercialization of EMPAVELI and SYFOVRE;
- our plans with respect to our ongoing and planned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and expectations regarding the anticipated results from these trials;
- our sales, marketing and distribution capabilities and strategies, including for the commercialization and manufacturing of EMPAVELI, SYFOVRE and any future products for which we receive marketing approval;
- the rate and degree of market acceptance of EMPAVELI, SYFOVRE and any future products for which we receive marketing approval;
- our ability to identify and develop current and future products or product candidates with significant clinical benefits and commercial potential;
- the timing of and our ability to obtain and maintain regulatory approvals for our product candidates for current and future treatment indications in the U.S. and other jurisdictions;
- our current and any future collaborations for the development and commercialization of our current and future product candidates; including our collaborations with Sobi and Beam Therapeutics, Inc.;
- our intellectual property position and strategy;
- the sufficiency of our cash and cash equivalents and our expected revenues from sales of EMPAVELI and SYFOVRE to fund our projected operating expenses and capital expenditures to profitability;
- our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
- developments relating to our competitors and our industry; and
- the impact of new government laws and regulations (including tax).

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, particularly in the “Risk Factors” section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed or incorporated by reference as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

This Quarterly Report on Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. All of the market data used in this Quarterly Report on Form 10-Q involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. We believe that the information from these industry publications, surveys and studies is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, including those described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. The Apellis, EMPAVELI, SYFOVRE and Apellis

[Table of Contents](#)

Assist names and logos are our trademarks, trade names and service marks. The other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

**Note regarding certain references in this Quarterly Report on Form 10-Q**

Unless otherwise stated or the context indicates otherwise, all references herein to “Apellis,” “Apellis Pharmaceuticals, Inc.,” “we,” “us,” “our,” “our company,” “the Company” and similar references refer to Apellis Pharmaceuticals, Inc. and its wholly owned subsidiaries.

In addition, unless otherwise stated or the context indicates otherwise, all references in this Quarterly Report on Form 10-Q to “EMPAVELI (pegcetacoplan)” and “EMPAVELI” refer to systemic pegcetacoplan in the context of the commercially available product in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria, or PNH, and C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older. References to Aspaveli refer to pegcetacoplan in the context of the commercially available product outside the United States for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months, in each case, as more fully described herein. Unless otherwise stated or the context indicates otherwise, all references in this Quarterly Report on Form 10-Q to “SYFOVRE (pegcetacoplan injection)” and “SYFOVRE” refer to intravitreal pegcetacoplan in the context of the commercially available product for which we received approval from the United States Food and Drug Administration in February 2023 for the treatment of geographic atrophy secondary to age-related macular degeneration. Unless otherwise stated or the context indicates otherwise, all references herein to “pegcetacoplan” refer to pegcetacoplan in the context of the product candidate for which we are exploring further applications and indications, as more fully described herein. The other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

**PART I—FINANCIAL INFORMATION****Item 1. Financial Statements.**

**APELLIS PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**(Unaudited)**  
**(Amounts in thousands, except per share amounts)**

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 479,171	\$ 411,290
Accounts receivable, net	345,538	264,926
Inventory	122,819	81,404
Prepaid assets	31,560	18,368
Restricted cash	1,430	1,322
Other current assets	10,158	11,644
Total current assets	<u>990,676</u>	<u>788,954</u>
<b>Non-current assets:</b>		
Right-of-use assets	19,720	16,083
Property and equipment, net	1,927	2,952
Long-term inventory	40,909	75,713
Other assets	5,491	1,349
Total assets	<u>\$ 1,058,723</u>	<u>\$ 885,051</u>
<b>Liabilities and Stockholders' Equity</b>		
<b>Current liabilities:</b>		
Accounts payable	\$ 38,602	\$ 38,572
Accrued expenses	140,322	140,184
Convertible senior notes	93,581	—
Current portion of lease liabilities	7,022	6,753
Total current liabilities	<u>279,527</u>	<u>185,509</u>
<b>Long-term liabilities:</b>		
Long-term credit facility	361,091	359,489
Convertible senior notes	—	93,341
Lease liabilities	13,680	10,201
Other liabilities	3,257	7,972
Total liabilities	<u>657,555</u>	<u>656,512</u>
Commitments and contingencies (Note 11)		
<b>Stockholders' equity:</b>		
Preferred stock, \$0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at September 30, 2025 and December 31, 2024	—	—
Common stock, \$0.0001 par value; 200,000 shares authorized at September 30, 2025 and December 31, 2024; 126,500 shares issued and outstanding at September 30, 2025, and 124,495 shares issued and outstanding at December 31, 2024	12	12
Additional paid-in capital	3,357,583	3,267,201
Accumulated other comprehensive loss	(2,400)	(3,308)
Accumulated deficit	(2,954,027)	(3,035,366)
Total stockholders' equity	<u>401,168</u>	<u>228,539</u>
Total liabilities and stockholders' equity	<u>\$ 1,058,723</u>	<u>\$ 885,051</u>

See accompanying notes to unaudited condensed consolidated financial statements.

**APELLIS PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS)**  
**(Unaudited)**  
**(Amounts in thousands, except per share amounts)**

	<u>For the Three Months Ended September 30,</u>		<u>For the Nine Months Ended September 30,</u>	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
<b>Revenue:</b>				
Product revenue, net	\$ 177,755	\$ 176,571	\$ 499,042	\$ 518,782
Licensing and other revenue	280,823	20,259	304,827	50,057
Total revenue:	<u>458,578</u>	<u>196,830</u>	<u>803,869</u>	<u>568,839</u>
<b>Operating expenses:</b>				
Cost of sales	24,531	33,557	72,517	76,867
Research and development	68,186	88,569	221,621	251,216
Selling, general and administrative	142,678	121,984	403,162	379,571
Total operating expenses:	<u>235,395</u>	<u>244,110</u>	<u>697,300</u>	<u>707,654</u>
Net operating income/(loss)	223,183	(47,280)	106,569	(138,815)
Loss on extinguishment of development liability	—	—	—	(1,949)
Interest income	4,376	2,889	9,641	9,377
Interest expense	(11,279)	(12,532)	(33,480)	(28,857)
Other income/(expense), net	37	70	18	(405)
Net income/(loss) before taxes	<u>216,317</u>	<u>(56,853)</u>	<u>82,748</u>	<u>(160,649)</u>
Income tax expense	602	592	1,409	876
Net income/(loss)	<u>\$ 215,715</u>	<u>\$ (57,445)</u>	<u>\$ 81,339</u>	<u>\$ (161,525)</u>
<b>Other comprehensive income/(loss):</b>				
Unrealized gain on pension benefits	137	—	137	—
Foreign currency translation	32	222	771	402
Total other comprehensive income	<u>169</u>	<u>222</u>	<u>908</u>	<u>402</u>
Comprehensive income/(loss), net of tax	<u>\$ 215,884</u>	<u>\$ (57,223)</u>	<u>\$ 82,247</u>	<u>\$ (161,123)</u>
<b>Net income/(loss) per share</b>				
Basic earnings per share	\$ 1.71	\$ (0.46)	\$ 0.65	\$ (1.31)
Diluted earnings per share	\$ 1.67	\$ (0.46)	\$ 0.65	\$ (1.31)
<b>Weighted-average shares used in calculating:</b>				
Basic earnings per share	126,424	124,234	125,971	123,698
Diluted earnings per share	130,067	124,234	129,653	123,698

See accompanying notes to unaudited condensed consolidated financial statements.

**APELLIS PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**  
**(Unaudited)**  
**(Amounts in thousands)**

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Stockholders' Equity
	Outstanding Shares	Amount				
Balance at January 1, 2025	124,495	\$ 12	\$ 3,267,201	\$ (3,308)	\$ (3,035,366)	\$ 228,539
Issuance of common stock upon exercise of stock options	15	—	281	—	—	281
Vesting of restricted stock units, net of shares withheld for taxes	1,151	—	(7)	—	—	(7)
Share-based compensation expense	—	—	27,374	—	—	27,374
Net loss	—	—	—	—	(92,225)	(92,225)
Foreign currency translation	—	—	—	254	—	254
Balance at March 31, 2025	125,661	\$ 12	\$ 3,294,849	\$ (3,054)	\$ (3,127,591)	\$ 164,216
Issuance of common stock upon exercise of stock options	310	—	4,367	—	—	4,367
Vesting of restricted stock units, net of shares withheld for taxes	82	—	—	—	—	—
Share-based compensation expense	—	—	27,197	—	—	27,197
Issuance of common stock under employee stock purchase plan	134	—	2,191	—	—	2,191
Net loss	—	—	—	—	(42,151)	(42,151)
Foreign currency translation	—	—	—	485	—	485
Balance at June 30, 2025	126,187	\$ 12	\$ 3,328,604	\$ (2,569)	\$ (3,169,742)	\$ 156,305
Issuance of common stock upon exercise of stock options	103	—	797	—	—	797
Vesting of restricted stock units, net of shares withheld for taxes	210	—	(4)	—	—	(4)
Share-based compensation expense	—	—	28,186	—	—	28,186
Unrealized gain on pension benefits	—	—	—	137	—	137
Net income	—	—	—	—	215,715	215,715
Foreign currency translation	—	—	—	32	—	32
Balance at September 30, 2025	126,500	\$ 12	\$ 3,357,583	\$ (2,400)	\$ (2,954,027)	\$ 401,168

See accompanying notes to unaudited condensed consolidated financial statements.

**APELLIS PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**  
(Continued from previous page)  
(Unaudited)  
(Amounts in thousands)

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Stockholders' Equity
	Outstanding Shares	Amount				
Balance at January 1, 2024	119,556	\$ 12	\$ 3,035,539	\$ (3,542)	\$ (2,837,488)	\$ 194,521
Proceeds from settlement of capped call	—	—	98,763	—	—	98,763
Issuance of common stock upon exercise of stock options	714	—	9,477	—	—	9,477
Vesting of restricted stock units, net of shares withheld for taxes	997	—	(28)	—	—	(28)
Share-based compensation expense	—	—	30,349	—	—	30,349
Net loss	—	—	—	—	(66,423)	(66,423)
Foreign currency translation	—	—	—	17	—	17
Balance at March 31, 2024	121,267	\$ 12	\$ 3,174,100	\$ (3,525)	\$ (2,903,911)	\$ 266,676
Issuance of common stock upon exercise of stock options	233	—	1,962	—	—	1,962
Vesting of restricted stock units, net of shares withheld for taxes	102	—	—	—	—	—
Share-based compensation expense	—	—	29,990	—	—	29,990
Issuance of common stock under employee stock purchase plan	85	—	3,193	—	—	3,193
Net loss	—	—	—	—	(37,657)	(37,657)
Foreign currency translation	—	—	—	163	—	163
Balance at June 30, 2024	121,687	\$ 12	\$ 3,209,245	\$ (3,362)	\$ (2,941,568)	\$ 264,327
Issuance of common stock upon exercise of stock options	112	—	2,556	—	—	2,556
Vesting of restricted stock units, net of shares withheld for taxes	270	—	(14)	—	—	(14)
Share-based compensation expense	—	—	27,475	—	—	27,475
Net loss	—	—	—	—	(57,445)	(57,445)
Foreign currency translation	—	—	—	222	—	222
Balance at September 30, 2024	122,069	\$ 12	\$ 3,239,262	\$ (3,140)	\$ (2,999,013)	\$ 237,121

See accompanying notes to unaudited condensed consolidated financial statements.

**APELLIS PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited)  
(Amounts in thousands)

	For the Nine Months Ended September 30,	
	2025	2024
<b>Operating Activities</b>		
Net income/(loss)	\$ 81,339	\$ (161,525)
Adjustments to reconcile net income/(loss) to net cash used in operating activities:		
Share-based compensation expense	82,757	87,814
Loss on extinguishment of development liability	—	1,949
Depreciation expense	1,231	1,350
Amortization of discounts for credit facility	1,602	742
Amortization of discounts for convertible notes	239	230
Accretion of discount to development liability	—	8,936
Changes in operating assets and liabilities:		
Accounts receivable	(80,605)	(72,569)
Inventory	(6,609)	(20,776)
Prepaid assets	(13,157)	15,022
Other current assets	1,642	10,651
Other assets	(4,181)	(81)
Right-of-use assets and lease liabilities	109	(7)
Accounts payable	28	(399)
Accrued expenses	(198)	12,072
Other current liabilities	—	1,903
Other liabilities	(4,694)	7,462
Net cash provided by/(used in) operating activities	59,503	(107,226)
<b>Investing Activities</b>		
Purchase of property and equipment	(205)	(383)
Net cash used in investing activities	(205)	(383)
<b>Financing Activities</b>		
Proceeds from credit facility	—	365,454
Payment of issuance cost for credit facility	—	(1,589)
Repayment of development liability	—	(326,533)
Proceeds from settlement of capped call	—	98,763
Proceeds from exercise of stock options	5,445	13,995
Proceeds from issuance of common stock under employee stock purchase plan	2,191	3,193
Payments of employee tax withholding related to equity-based compensation	(11)	(42)
Net cash provided by financing activities	7,625	153,241
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1,066	306
Net increase in cash, cash equivalents and restricted cash	67,989	45,938
Cash, cash equivalents and restricted cash at beginning of period	412,612	352,299
Cash, cash equivalents and restricted cash at end of period	\$ 480,601	\$ 398,237
<b>Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:</b>		
Cash and cash equivalents	\$ 479,171	\$ 396,864
Restricted cash	1,430	1,373
Total cash, cash equivalents, and restricted cash	\$ 480,601	\$ 398,237
<b>Supplemental Disclosures</b>		
Cash paid for interest	\$ 31,888	\$ 19,446
Cash paid for income taxes	\$ 847	\$ 600
Lease assets obtained in exchange for operating lease liabilities	\$ 6,457	\$ —
Issuance costs for credit facility incurred but not yet paid	\$ —	\$ 5,625

See accompanying notes to unaudited condensed consolidated financial statements.

**APELLIS PHARMACEUTICALS, INC.**  
**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(unaudited)**

**1. Nature of Organization and Operations**

Apellis Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company’s principal executive offices are located in Waltham, Massachusetts.

The Company’s operations since inception have included organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital, developing its product candidates, commercializing EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (“PNH”), C3 glomerulopathy (“C3G”) and primary immune complex membranoproliferative glomerulonephritis (“IC-MPGN”), and commercializing SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy secondary to age-related macular degeneration (“GA”).

The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”).

***Liquidity and Going Concern***

The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. From inception to September 30, 2025, the Company has incurred cash outflows from operations, losses from operations and had an accumulated deficit of \$3.0 billion, primarily as a result of expenses incurred through a combination of research and development activities related to the Company’s various product candidates and expenses supporting those activities and expenses incurred in connection with product launches and commercialization costs.

As of October 30, 2025, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents of \$479.2 million as of September 30, 2025, combined with cash anticipated to be generated from sales of EMPAVELI and from SYFOVRE, will be sufficient to fund its operations and capital expenditure requirements for at least twelve months from the date of issuance of these condensed consolidated financial statements.

**2. Basis of Presentation and Summary of Significant Accounting Policies**

***Basis of Presentation***

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted and, accordingly, the condensed consolidated balance sheet as of December 31, 2024 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of the Company’s financial information. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for any other interim period or for any other future year.

## [Table of Contents](#)

The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024 included in the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2025 (the "2024 Form 10-K").

### ***Use of Estimates***

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: accrued research and development expenses, reserves for variable consideration, share-based compensation expense and reserves for excess or obsolete inventories.

### ***Summary of Significant Accounting Policies***

Reference is made to Note 2 *Summary of Significant Accounting Policies* in our 2024 Form 10-K for a detailed description of significant accounting policies. There have been no significant changes to our accounting policies as disclosed in our 2024 Form 10-K.

### ***Recent Accounting Pronouncements issued not yet adopted***

In September 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2025-06, *Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Improvements to Capitalization of Software Development Costs*, which updates the accounting guidance for internal-use software costs and removes references to prescriptive project stages. The ASU is effective for annual periods beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the timing of adoption and the impact of the new guidance on the condensed consolidated financial statements and related disclosures.

In July 2025, the FASB issued ASU 2025-05, *Measurement of Credit Losses for Accounts Receivable and Contract Assets*, which provides a practical expedient to measure credit losses on accounts receivable and contract assets. The ASU is effective for annual periods beginning after December 15, 2025, and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the timing of the adoption and the impact of the new guidance on the condensed consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*, and subsequent amendments with ASU 2025-01, which requires additional disclosure of the nature of expenses included in the income statement. The standard requires disclosures about specific types of expenses included in the expense captions presented in the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its disclosures.

In December 2023, the FASB issued ASU 2023-09, *Improvements to Income Tax Disclosures*. This standard is an amendment to the accounting guidance on income taxes which requires entities to provide additional information in the rate reconciliation and additional disaggregated disclosures about income taxes paid. This guidance requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state, and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. The guidance is effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact the adoption of this guidance will have on its disclosures.

### **3. Product Revenues, Accounts Receivable, and Reserves for Product Sales**

The table reflects product revenue by major source for the following periods (in thousands):

[Table of Contents](#)

	Therapeutic Area	Key Indications	Three Months Ended September 30,		Nine Months Ended September 30,	
			2025	2024	2025	2024
Products:						
EMPAVELI	Rare Disease	PNH, C3G (1), IC-MPGN (1)	\$ 26,827	\$ 24,611	\$ 67,315	\$ 74,733
SYFOVRE	Ophthalmology	GA	150,928	151,960	431,727	444,049
Total Product revenue, net			<u>\$ 177,755</u>	<u>\$ 176,571</u>	<u>\$ 499,042</u>	<u>\$ 518,782</u>

(1) The FDA approved EMPAVELI for the treatment of C3G and IC-MPGN on July 28, 2025.

The Company's accounts receivable balance of \$345.5 million as of September 30, 2025 and \$264.9 million as of December 31, 2024, consisted of EMPAVELI and SYFOVRE product sales receivable. The Company does not have a reserve related to expected credit losses against its accounts receivable balance and expects to collect its accounts receivable in the ordinary course of business.

The Company's product sales reserves totaled \$47.4 million and \$45.1 million as of September 30, 2025 and December 31, 2024, respectively. These amounts are included in accrued expenses on the Company's unaudited condensed consolidated balance sheets.

The following table summarizes activity in each of the product revenue allowance and reserve categories for the three and nine months ended September 30, 2025 (in thousands):

	Fees and patient assistance	Government and other rebates	Returns	Total
Ending balance at December 31, 2024	\$ 11,589	\$ 31,533	\$ 2,023	\$ 45,145
Provision related to sales in the current period	10,277	24,139	976	35,392
Adjustments related to prior period sales	439	(13)	(382)	44
Credits and payments made	(13,084)	(28,467)	(126)	(41,677)
Ending balance at March 31, 2025	\$ 9,221	\$ 27,192	\$ 2,491	\$ 38,904
Provision related to sales in the current period	12,138	30,823	1,083	44,044
Adjustments related to prior period sales	(66)	185	852	971
Credits and payments made	(10,833)	(27,623)	(941)	(39,397)
Ending balance at June 30, 2025	\$ 10,460	\$ 30,577	\$ 3,485	\$ 44,522
Provision related to sales in the current period	12,695	38,426	1,152	52,273
Adjustments related to prior period sales	366	(12)	(211)	143
Credits and payments made	(12,436)	(34,730)	(2,324)	(49,490)
Ending balance at September 30, 2025	<u>\$ 11,085</u>	<u>\$ 34,261</u>	<u>\$ 2,102</u>	<u>\$ 47,448</u>

The following table summarizes activity in each of the product revenue allowance and reserve categories for the three and nine months ended September 30, 2024 (in thousands):

[Table of Contents](#)

	Fees and patient assistance	Government and other rebates	Returns	Total
Ending balance at December 31, 2023	\$ 5,674	\$ 8,898	\$ 2,053	\$ 16,625
Provision related to sales in the current period	9,575	13,125	1,355	24,055
Adjustments related to prior period sales	146	(19)	(96)	31
Credits and payments made	(9,724)	(9,906)	(1,859)	(21,489)
Ending balance at March 31, 2024	\$ 5,671	\$ 12,098	\$ 1,453	\$ 19,222
Provision related to sales in the current period	10,025	17,777	1,039	28,841
Adjustments related to prior period sales	(131)	354	(983)	(760)
Credits and payments made	(9,635)	(14,640)	(326)	(24,601)
Ending balance at June 30, 2024	\$ 5,930	\$ 15,589	\$ 1,183	\$ 22,702
Provision related to sales in the current period	11,455	25,364	1,380	38,199
Adjustments related to prior period sales	2,332	420	—	2,752
Credits and payments made	(12,078)	(17,695)	(979)	(30,752)
Ending balance at September 30, 2024	\$ 7,639	\$ 23,678	\$ 1,584	\$ 32,901

Significant customers - Gross product revenues and product sales receivable from the Company's customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total product sales receivable consisted of the following:

	Percent of Total Gross Product Revenues			
	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Customer A	13%	12%	12%	13%
Customer C	21%	17%	19%	18%
Customer D	58%	61%	59%	59%

	Percent of Product Sales Receivable	
	As of September 30,	
	2025	2024
Customer A	4%	3%
Customer C	21%	24%
Customer D	67%	61%

Factoring of accounts receivable and associated fees for the three and nine months ended September 30, 2025 and 2024 were as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Accounts receivable sold	\$ —	\$ 56,590	\$ 199,448	\$ 56,590
Less: factoring fees	—	(672)	(2,433)	(672)
Net cash proceeds	\$ —	\$ 55,918	\$ 197,015	\$ 55,918

Accounts receivable sold that remained outstanding as of September 30, 2025 and December 31, 2024 totaled zero and \$86.1 million, respectively.

#### 4. Inventory

The Company's inventory consisted of the following as of September 30, 2025 and December 31, 2024 (in thousands):

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Raw materials	\$ 52,183	\$ 54,385
Semi-finished goods	107,463	92,872
Finished goods	4,082	9,860
Total inventory	<u>\$ 163,728</u>	<u>\$ 157,117</u>

The Company's long-term inventory balance consists of raw materials as of September 30, 2025, and raw materials and semi-finished goods as of December 31, 2024, that are not expected to be sold within the Company's normal operating cycle.

Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales. The Company's reserve for excess and obsolete inventory was \$19.6 million and \$19.0 million as of September 30, 2025 and December 31, 2024, respectively.

#### 5. Prepaid and Other Current Assets

Prepaid and other current assets consisted of the following as of September 30, 2025 and December 31, 2024 (in thousands):

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Down payments for inventory	\$ 970	\$ 1,080
Prepaid research and development	20,156	7,780
Other prepaid expenses	10,434	9,508
Total prepaid assets	<u>\$ 31,560</u>	<u>\$ 18,368</u>

  

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Royalties receivable	\$ 6,534	\$ 4,525
Receivable from collaboration agreement	2,563	2,272
Deposits and other current assets	1,061	4,847
Total other current assets	<u>\$ 10,158</u>	<u>\$ 11,644</u>

#### 6. Accrued Expenses

Accrued expenses consisted of the following as of September 30, 2025 and December 31, 2024 (in thousands):

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Accrued research and development	\$ 17,525	\$ 22,782
Accrued royalties	7,059	7,147
Accrued payroll liabilities	32,542	40,888
Accrued goods received not invoiced	3,498	638
Product revenue reserves	47,448	45,145
Commercial costs	27,588	20,610
Other	4,662	2,974
Total accrued expenses	<u>\$ 140,322</u>	<u>\$ 140,184</u>

## 7. Long-term Debt

### *Convertible Senior Notes*

On September 16, 2019, the Company completed a private offering of convertible notes (the “2019 Convertible Notes”) with an aggregate principal amount of \$220.0 million issued pursuant to an indenture (the “Indenture”) with U.S. Bank National Association, as trustee.

The net proceeds from the sale of the 2019 Convertible Notes were approximately \$212.9 million after deducting the initial purchasers’ discounts and commissions of \$6.6 million and offering expenses of \$0.5 million paid by the Company. The Company used \$28.4 million of the net proceeds from the sale of the 2019 Convertible Notes to pay the cost of the capped call transactions in September 2019, described below.

On May 12, 2020, the Company issued convertible notes (the “2020 Convertible Notes”) with an aggregate principal amount of \$300.0 million. The net proceeds from the sale of the 2020 Convertible Notes were approximately \$322.9 million after deducting the purchasers’ discounts and commission of \$5.7 million and offering expenses of \$0.3 million. The Company used \$43.1 million of the net proceeds from the sale of the 2020 Convertible Notes to pay the cost of the additional capped call transactions in May 2020, described below.

The 2019 Convertible Notes and the 2020 Convertible Notes are referred to together as the “Convertible Notes”. The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 3.5% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2020. The Convertible Notes will mature on September 15, 2026, unless converted earlier, redeemed or repurchased in accordance with their terms.

The Convertible Notes are convertible into shares of the Company’s common stock at an initial conversion rate of 25.3405 shares per \$1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately \$39.4625 per share of common stock). The conversion rate is subject to customary anti-dilution adjustments. In addition, following certain events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or a notice of redemption, as the case may be, in certain circumstances as provided in the Indenture.

Prior to March 15, 2026, the Convertible Notes are convertible only under the following circumstances:

- during any calendar quarter, if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
- during the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the Convertible Notes for each such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day;
- if the Company calls any or all of the Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or
- upon the occurrence of corporate events specified in the Indenture.

On or after March 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date of the Convertible Notes, holders may convert the Convertible Notes at any time. Upon conversion of the Convertible Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the Company’s election.

After September 20, 2023, the Company may redeem for cash all or a portion of the Convertible Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides a notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company calls any Convertible Notes for redemption, it will constitute a “make-whole fundamental change” with respect to such Convertible Notes, in which case the conversion rate applicable to the conversion of such Notes, if converted in connection with the redemption, will be increased in certain circumstances. The Company has not called for redemption or redeemed any of the Convertible Notes as of September 30, 2025.

[Table of Contents](#)

If the Company undergoes a “fundamental change,” as defined in the Indenture, prior to maturity, subject to certain conditions, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

In January 2021, July 2021 and July 2022, the Company entered into separate, privately negotiated exchange agreements to modify the conversion terms with certain holders of its 2019 Convertible Notes and 2020 Convertible Notes. Under the terms of these exchange agreements, in January 2021, July 2021 and July 2022, the holders exchanged approximately \$126.1 million of 2019 Convertible Notes, \$201.1 million of 2019 Convertible Notes and 2020 Convertible Notes, and \$98.1 million of 2020 Convertible Notes, respectively, in aggregate principal amount held by them for an aggregate of 3,906,869 shares, 5,992,217 shares and 3,027,018 shares, respectively, of common stock issued by the Company. The Company accounted for the conversion of the debt as an inducement by expensing the fair value of the shares that were issued in excess of the original terms of the Convertible Notes.

The conditional conversion feature of the Convertible Notes was not triggered as of September 30, 2025 and as of December 31, 2024.

As of September 30, 2025, the Company held in treasury Convertible Notes in principal amount of \$425.4 million which have not been cancelled.

As the Convertible Notes mature on September 15, 2026, the Company classified these as current as of September 30, 2025 and non-current as of December 31, 2024 on the Company’s unaudited condensed consolidated balance sheets.

The outstanding balance of the Convertible Notes as of September 30, 2025 and December 31, 2024 consisted of the following (in thousands):

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Principal	\$ 93,897	\$ 93,897
Less: debt discount and issuance costs, net	(316)	(556)
Net carrying amount	<u>\$ 93,581</u>	<u>\$ 93,341</u>

The following table sets forth total interest expense recognized related to the Convertible Notes during the three and nine months ended September 30, 2025 and 2024 (in thousands):

	<u>Three Months Ended September 30,</u>		<u>Nine Months Ended September 30,</u>	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Amortization of debt issuance costs	\$ 81	\$ 78	\$ 239	\$ 230
Contractual interest expense	822	822	2,465	2,465
Total interest expense	<u>\$ 903</u>	<u>\$ 900</u>	<u>\$ 2,704</u>	<u>\$ 2,695</u>

### ***Capped Call Transactions***

On September 11, 2019 and May 6, 2020, concurrently with the pricing of the 2019 Convertible Notes and the 2020 Convertible Notes, respectively, the Company entered into capped call transactions with two counterparties. The capped call transactions are expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Convertible Notes, as the case may be, in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which is initially \$39.4625 (the conversion price of the Convertible Notes) and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of such Convertible Notes. If, however, the market price per share of the Company’s common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, which is initially \$63.14 per share, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.

On February 27, 2024, the Company unwound a portion of the capped call transactions with the capped call counterparties, which resulted in cash proceeds to the Company of \$98.8 million. The unwind transactions were settled at a volume-weighted average price per share of \$64.11 on March 8, 2024.

[Table of Contents](#)

As of September 30, 2025, the Company holds remaining capped call transactions in a notional amount corresponding to \$93.9 million principal amount of Convertible Notes.

**Financing Agreement and Credit Facility**

On May 13, 2024, the Company and certain of its subsidiaries entered into a financing agreement (the “Sixth Street Financing Agreement”) with the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners (“Sixth Street”), as the administrative agent and collateral agent for the Lenders.

The Sixth Street Financing Agreement provides for a senior secured term loan facility of up to \$475.0 million (the “Credit Facility”), consisting of an initial draw of \$375.0 million at closing and a potential additional \$100.0 million draw at the Company’s option upon satisfaction of a \$50.0 million minimum cash requirement and a requirement that the Company’s trailing three-month sales of SYFOVRE is at least \$180.0 million prior to the \$100.0 million draw by September 30, 2025. The Company did not draw down the additional \$100.0 million and the option expired September 30, 2025.

The Credit Facility matures on May 13, 2030 (the “Maturity Date”) and bears interest at an annual rate equal to 3-month Secured Overnight Financing Rate (“SOFR”) (subject to 1.00% floor), plus 5.75%. Certain additional commitment and undrawn amount fees are also payable in connection with the Credit Facility.

The net proceeds from the initial draw of the Credit Facility were approximately \$358.2 million, net of \$16.8 million of issuance costs. The Company used \$326.5 million of the proceeds from the initial draw of the Credit Facility to buy out its remaining obligations to SFJ Pharmaceuticals Group (“SFJ”).

The Credit Facility does not provide for scheduled amortization payments during the term. All principal will be due on the Maturity Date. The Company has the right to prepay loans under the Credit Facility at any time. The Company is required to repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. Repayments are subject to a prepayment premium. Repayments may be made after the first year of the loan (one year from May 13, 2024) and are subject to a prepayment premium up to 3% depending on timing.

On July 1, 2025, the Lenders and Sixth Street consented to the Royalty Agreement as further described in Note 10 (the “Consent”). In connection with the Consent, the Company agreed to extend by one year from the effective date of the Consent the periods in which certain prepayment premiums would be owed under the Sixth Street Financing Agreement. This effectively extended the period the prepayment premium would be owed from one year after the date of the initial draw, or May 13, 2024, to one year after the effective date of the Consent, or July 1, 2025.

All obligations under the Sixth Street Financing Agreement are secured on a first-priority basis, subject to certain exceptions, by security interests in substantially all assets of the Company and certain subsidiaries of the Company, including its intellectual property, and are guaranteed by certain subsidiaries of the Company, including foreign subsidiaries, subject to certain exceptions.

The Sixth Street Financing Agreement contains customary covenants, including, without limitation, a financial covenant to maintain liquidity of at least \$50.0 million if the Company’s market capitalization is below \$3.0 billion, and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, and other matters customarily restricted in such agreements. Among other permissions, the Company is permitted, on terms and conditions set forth on the Sixth Street Financing Agreement, to enter into a separate asset-based financing arrangement with a third party in an amount of up to \$100.0 million, which amount is increased to \$200.0 million upon certain sales or market capitalization thresholds, and to have outstanding convertible unsecured notes in an amount equal to the greater of \$400.0 million and 10% of the Company’s market capitalization, but not to exceed \$600.0 million. The Company is subject to restrictions on sales and licensing transactions with respect to its core intellectual property, defined to include SYFOVRE, EMPAVELI, and other pegcetacoplan product assets, subject to certain exceptions, including certain transactions related to areas outside the United States and Europe.

The outstanding balance of the Credit Facility as of September 30, 2025 and December 31, 2024 consisted of the following (in thousands):

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Principal	\$ 375,000	\$ 375,000
Less: debt discount and issuance costs	(13,909)	(15,511)
Net carrying amount	<u>\$ 361,091</u>	<u>\$ 359,489</u>

[Table of Contents](#)

The following table sets forth total interest expense recognized related to the Credit Facility during the three and nine months ended September 30, 2025 and 2024 (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Amortization of debt issuance costs	\$ 556	\$ 581	\$ 1,602	\$ 742
Contractual interest expense	9,627	10,854	28,602	16,160
Total interest expense	<u>\$ 10,183</u>	<u>\$ 11,435</u>	<u>\$ 30,204</u>	<u>\$ 16,902</u>

## 8. Fair Value Measurements

The following table presents the fair value of financial instruments recorded originally at amortized cost or fair value and are not remeasured on a recurring basis (in thousands):

Balance Sheet Classification	Type of Instrument	September 30, 2025			
		Level 1	Level 2	Level 3	Total
Financial Assets:					
Cash and cash equivalents:	Money market funds	\$ 215,630	\$ —	\$ —	\$ 215,630
Total Financial Assets		<u>\$ 215,630</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 215,630</u>

  

Balance Sheet Classification	Type of Instrument	December 31, 2024			
		Level 1	Level 2	Level 3	Total
Financial Assets:					
Cash and cash equivalents	Money market funds	\$ 276,868	\$ —	\$ —	\$ 276,868
Total Financial Assets		<u>\$ 276,868</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 276,868</u>

The Company's Convertible Notes are financial instruments that are reported in the condensed consolidated financial statements at historical cost. The Convertible Notes are Level 1 within the fair value level hierarchy as of September 30, 2025 and December 31, 2024. The fair value of the Convertible Notes was \$94.0 million as of September 30, 2025 and \$102.3 million as of December 31, 2024. The Convertible Notes accrue a semi-annual coupon at an annual rate of 3.5%, which was included in accrued expenses in the consolidated balance sheets as of September 30, 2025 and December 31, 2024.

The Company believes that the carrying amounts of remaining financial assets and liabilities, which include other current assets, accounts payable, and accrued expenses, approximates their fair values due to their short-term nature.

## 9. Income Taxes

The income tax provision during interim periods is computed by applying an estimated annual effective tax rate to year-to-date pre-tax income, plus adjustments for significant unusual or infrequently occurring items, in accordance with FASB ASC Topic 740-270, Income Taxes – Interim Reporting. The income tax provision differs from the U.S. federal statutory rate of 21% primarily due to the effect of valuation allowance against the Company's net deferred tax assets, which reduces the Company's net tax benefit.

Deferred tax assets and deferred tax liabilities are determined based on temporary differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has recorded a full valuation allowance against its net deferred tax assets as of September 30, 2025 and December 31, 2024.

The Company does not recognize a tax benefit for uncertain tax positions unless it is more likely than not that the position will be sustained upon examination by tax authorities, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of cumulative benefit that has greater than a 50 percent likelihood of being realized upon ultimate settlement. Deferred tax assets that do not meet these recognition criteria are not recorded and the Company recognizes a liability for uncertain tax positions that may result in tax payments. The Company has not recorded any amounts for unrecognized tax positions for the period ended September 30, 2025. The Company's policy is to review and update unrecognized tax positions as facts and circumstances change.

## [Table of Contents](#)

On July 4, 2025, The One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes significant tax provisions, such as permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The new legislation did not have a material impact on the Company's tax provision during the quarter.

The Company recorded \$0.6 million and \$1.4 million of income tax expense for the three and nine months ended September 30, 2025, respectively, and \$0.6 million and \$0.9 million of income tax expense for the three and nine months ended September 30, 2024, respectively. The provision for income taxes consists of current tax expense, which relates primarily to the Company's state and foreign tax jurisdictions where net operating loss carryforwards were either limited or not available.

## **10. License and Collaboration Agreements**

### ***Sobi License and Collaboration Agreement***

In October 2020, the Company and its subsidiaries, Apellis International GmbH (f/k/a Apellis Switzerland GmbH) and APL DEL Holdings, LLC, entered into a Collaboration and License Agreement (the “Sobi collaboration agreement”) with Sobi, concerning the development and commercialization of pegcetacoplan and specified other structurally and functionally similar compstatin analogues or derivatives for use systemically or for local non-ophthalmological administration (collectively referred to as the “Licensed Products”).

Under the Sobi collaboration agreement, the Company granted Sobi an exclusive (subject to certain retained rights of the Company), sublicensable license of certain patent rights and know-how to develop and commercialize Licensed Products in all countries outside of the United States.

The Company retains the right to commercialize Licensed Products in the United States, and, subject to specified limitations, to develop Licensed Products worldwide for commercialization in the United States.

Under the Sobi collaboration agreement, the Company and Sobi agreed to collaborate to develop Licensed Products for certain indications, including PNH, C3G, IC-MPGN and HSCT-TMA (collectively the “Initial Indications”), and any other indications subsequently agreed upon by the parties, for commercialization by or on behalf of the Company in the United States and by or on behalf of Sobi outside of the United States. If the parties do not agree to jointly pursue any development activities for the Licensed Products (whether for an Initial Indication or otherwise), the party proposing to pursue such activities may conduct such activities at its sole expense (with the non-proposing party having the right to obtain rights to the data generated by such development activities by paying a specified percentage of that expense), subject to agreed-upon exceptions that limit each party's unilateral development rights. In July 2025, the Company and Sobi decided to discontinue development of systemic pegcetacoplan for Transplant-associated Thrombotic Microangiopathy (TA-TMA) (inclusive of HSCT-TMA), following completion of the Phase 2 study and a strategic assessment of the TA-TMA market landscape.

The initial development plan sets forth the initial development activities to be conducted by each of the Company and Sobi, with the Company bearing all costs incurred in conducting the activities set forth in such initial development plan, as well as certain specified additional costs that are not included in the initial development plan that may be incurred by the parties in developing Licensed Products for PNH in the European Union and the United Kingdom. The Company and Sobi formed several governance committees to oversee the development and manufacture, and to review and discuss the commercialization, of Licensed Products.

The Company shall supply Licensed Products to Sobi for development and for commercialization outside of the United States in accordance with a supply agreement between the parties. The Sobi collaboration agreement grants Sobi the right to perform or have performed drug product manufacturing of Licensed Products for development and for commercialization outside the United States and to manufacture or have manufactured drug substance under certain circumstances. For the three and nine months ended September 30, 2025 the Company recognized revenues of \$5.2 million and \$17.2 million, respectively, for the supply of Licensed Products to Sobi, which is included in Licensing and other revenue on the condensed consolidated statements of operations and comprehensive income/(loss). For the three and nine months ended September 30, 2024 the Company recognized revenues of \$15.3 million and \$36.2 million, respectively, for the supply of Licensed Products to Sobi, which is included in Licensing and other revenue on the condensed consolidated statements of operations and comprehensive income/(loss).

Sobi paid the Company an upfront payment of \$250.0 million in November 2020 and has agreed to pay up to an aggregate of \$915.0 million upon the achievement of specified one-time regulatory and commercial milestone events, of which the Company received \$50.0 million in April 2022 for the achievement of a regulatory development milestone in Europe. Sobi also agreed to reimburse the Company for up to \$80.0 million in development costs, of which the Company received \$65.0 million and waived payment of \$15.0 million. The Company will also be entitled to receive tiered, double-digit royalties (ranging from high teens to high twenties) on sales

## [Table of Contents](#)

of Licensed Products outside of the United States, subject to customary deductions and third-party payment obligations, until the latest to occur of: (i) expiration of the last-to-expire of specified licensed patent rights; (ii) expiration of regulatory exclusivity; and (iii) ten (10) years after the first commercial sale of the applicable Licensed Product, in each case on a Licensed Product-by-Licensed Product and country-by-country basis. Under the Sobi collaboration agreement, the Company remains responsible for its license fee obligations (including royalty obligations) to the Trustees of the University of Pennsylvania ("Penn"), as a licensor of the Company.

On July 1, 2025 (the "Closing Date"), Apellis Pharmaceuticals, Inc. and its subsidiaries Apellis International GmbH and APL DEL Holdings, LLC (collectively, the "Company") entered into a Royalty Buy-Down Agreement (the "Royalty Agreement") with Sobi.

Under the Royalty Agreement, Sobi paid the Company an upfront payment of \$275.0 million and agreed to pay up to an aggregate of \$25.0 million upon the European Medicines Agency ("EMA") approval of Aspaveli for C3G and IC-MPGN (collectively, the "purchase price"), and the Company agreed to reduce Sobi's royalty payment obligations under the Sobi collaboration agreement by 90%, effective July 1, 2025. The royalty reduction is subject to defined caps tied to Aspaveli's performance, including an initial cap of 1.45x of the purchase price.

The royalty reduction subject to the cap is calculated as an amount equal to (A) the royalty payments that would have been payable by Sobi under the Sobi collaboration agreement with respect to aggregate net sales of Aspaveli in the Sobi Territory during the period beginning on July 1, 2025 and ending on the hard cap achievement date if the 90% reduction not been applied, minus (B) the royalty payments that are payable to the Company with the 90% reduction in effect. At any time on or after October 1, 2030, the Company may elect to pay Sobi a one-time payment amount, which shall be counted in determining if a cap is met. If a cap is met, Sobi's royalty payment obligations under the Sobi collaboration agreement will revert to 100%.

The Company has evaluated the terms of the Royalty Agreement and concluded, in accordance with *ASC 606 Revenue from Contracts with Customers*, the Royalty Agreement is a modification to, and should be accounted for as if it were part of, the existing Sobi collaboration agreement. Therefore, the effect of the modification on the transaction price, being the addition of the \$275.0 million upfront payment, was recognized as an adjustment to revenue on the date of the modification. This amount is reflected in licensing and other revenue on the condensed consolidated statement of operations and comprehensive income/(loss) for the three and nine months ended September 30, 2025. The royalty revenues from the sales of Aspaveli will continue to be recorded as licensing and other revenue on the condensed consolidated statement of operations and comprehensive income/(loss) as the sales are made by Sobi outside of the United States.

Under the Sobi collaboration agreement, for the three and nine months ended September 30, 2025, the Company recognized \$0.6 million and \$12.6 million, respectively, of royalty revenue from sales of Aspaveli, which was sold by Sobi outside of the United States. For the three and nine months ended September 30, 2024, the Company recognized \$5.0 million and \$13.9 million, respectively, of royalty revenue from sales of Aspaveli, which was sold by Sobi outside of the United States.

The Company did not recognize any contra-research and development expense for the three and nine months ended September 30, 2025 and 2024. The Company doesn't expect to recognize the additional contra-research and development expense under this agreement.

### ***University of Pennsylvania License Agreements***

#### ***Patent License Agreement with Penn (Non-ophthalmic Fields of Use)***

The Company is party to a license agreement with Penn for an exclusive, worldwide license to specified patent rights for the development and commercialization of products in fields of use, as defined therein. The Company is required to make milestone payments aggregating up to \$1.7 million, based upon the achievement of development and regulatory approval milestones, and up to \$2.5 million, based upon the achievement of annual sales milestones with respect to each of the first two licensed products. The license agreement also requires the Company to pay low single digit royalties based on net sales of each licensed product, subject to minimum quarterly royalty thresholds. In addition, the Company is obligated to pay a specified portion of income it receives from sublicensees.

In January 2021, the Company paid \$25.0 million for a sublicense fee owed to Penn related to the Sobi collaboration agreement and another licensing transaction. In August 2021, the Company paid \$1.0 million to Penn upon the achievement of a development milestone, net of a credit for the annual license maintenance payment. In June 2022, the Company paid an additional \$5.0 million to Penn for a sublicense fee related to the Sobi collaboration agreement. In January 2023, the Company paid \$1.0 million to Penn upon the achievement of a sales milestone for EMPAVELI in 2022. In January 2024, the Company paid \$0.5 million for a sublicense fee owed to Penn related to Sobi obtaining regulatory approval in Japan. Additionally, in January 2024, the Company paid \$1.5 million as a result of the achievement of a sales milestone for EMPAVELI and Aspaveli.

For the three and nine months ended September 30, 2025, the Company incurred royalty expense of \$2.0 million and \$5.3 million,

## [Table of Contents](#)

respectively, on sales of EMPAVELI and Aspaveli which is included in cost of sales on the condensed consolidated statements of operations and comprehensive income/(loss).

For the three and nine months ended September 30, 2024, the Company incurred royalty expense of \$1.8 million and \$5.0 million, respectively, on sales of EMPAVELI and Aspaveli which is included in cost of sales on the condensed consolidated statements of operations and comprehensive income/(loss).

### *Amended and Restated Patent License Agreement with Penn (Ophthalmic Field of Use)*

The Company is also party to a license agreement with Penn for an exclusive, worldwide license to specified patent rights. The Company is required to make milestone payments aggregating up to \$3.2 million based upon the achievement of specified development and regulatory milestones and up to \$5.0 million based upon the achievement of specified annual sales milestones with respect to each licensed product, and to pay low single-digit royalties based on net sales of each licensed product and with minimum quarterly royalty thresholds. In addition, the Company is obligated to pay a specified portion of income it receives from sublicensees.

In April 2023, the Company paid \$2.3 million for the achievement of a regulatory milestone as a result of the FDA approval of SYFOVRE in February 2023. In 2023, the Company incurred \$5.0 million as a result of the achievement of sales milestones for SYFOVRE of which the Company paid \$2.0 million in October 2023 and the remaining \$3.0 million in January 2024.

For the three and nine months ended September 30, 2025, the Company incurred royalty expense of \$4.9 million and \$14.1 million, respectively, on sales of SYFOVRE, which is included in cost of sales on the condensed consolidated statements of operations and comprehensive income/(loss).

For the three and nine months ended September 30, 2024, the Company incurred royalty expense of \$4.9 million and \$14.4 million, respectively, on sales of SYFOVRE, which is included in cost of sales on the condensed consolidated statements of operations and comprehensive income/(loss).

### **Beam Research Collaboration**

In June 2021, the Company entered into an exclusive five-year research collaboration (the "Beam collaboration agreement") with Beam Therapeutics, Inc. ("Beam") focused on the use of Beam's proprietary base editing technology to discover new treatments for complement-driven diseases. The Company and Beam agreed to collaborate on up to six research programs focused on C3 and other complement targets in the eye, liver and brain. Under the terms of the Beam collaboration agreement, the Company is responsible for selecting specific genes within the complement system in various organs including the eye, liver and brain (the "Target List") and providing analytical support while Beam will apply its base editing technology and conduct preclinical research on up to six base editing programs for the Target List. During the first five years of the Beam collaboration agreement, Beam is prohibited from developing on its own or with a third party any base editing therapies associated with the items on the Target List but does not prevent Beam from licensing its intellectual property to a third-party for another purpose outside of the Target List. The Company will have exclusive rights to license each of the six programs and will assume responsibility for subsequent development and commercialization. Beam may elect to enter a 50-50 co-development and U.S. co-commercialization agreement with the Company with respect to any one program licensed under the Beam collaboration agreement and upon such election any license agreement in place at that time, would be terminated.

As part of the Beam collaboration agreement, the Company agreed to pay a \$50.0 million up-front, non-refundable payment to Beam, which the Company paid in July 2021. The Company paid an additional \$25.0 million on the first anniversary of the Beam collaboration agreement in June 2022. The Company and Beam are each responsible for their own costs during the research collaboration. If and after the opt-in license rights are exercised for each of the six programs, Beam will be eligible to receive development, regulatory and sales milestones from the Company, as well as royalty payments on sales. The Beam collaboration agreement has an initial term of five years and may be extended up to two years on a per year program-by-program basis.

Further, in August 2025, the Company opted in and entered into a license agreement with Beam to collaborate on the neonatal Fc receptor ("FcRn") in the liver, which triggered an upfront milestone payment of \$3.8 million, paid in September 2025. Under this agreement, the Company may pay Beam up to \$168.8 million in regulatory and development milestones, up to \$215.0 million in sales-based milestones, and may owe low single-digit royalties on annual net sales within the licensed territory.

## **11. Commitments and Contingencies**

The Company has certain non-cancelable purchase obligations related to the manufacturing of drug substance. The Company has agreed to purchase from Bachem Americas, Inc. a significant portion of its requirements for the pegcetacoplan drug substance. Under a commercial supply agreement with NOF Corporation ("NOF"), the Company has agreed to purchase activated polyethylene glycol derivative, or PEG, which is a component of pegcetacoplan. In September 2024, the Company terminated the minimum purchase

## [Table of Contents](#)

obligation with NOF for 2025. Under these agreements, as of September 30, 2025, the Company is obligated to pay up to \$94.7 million to these vendors over the next two years. As a result of the termination of the minimum purchase obligation with NOF, the Company incurred an expense of \$6.4 million, which was included in cost of sales on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. As this amount is due in January 2026, it is included in accounts payable on the condensed consolidated balance sheet as of September 30, 2025 and included in other liabilities on the condensed consolidated balance sheet as December 31, 2024.

In addition, the Company has other non-cancelable purchase agreements as of September 30, 2025, under which it is obligated to pay up to \$11.5 million to vendors over the next five years.

The Company is a party to a master lease agreement under which the Company leases vehicles with initial terms of 36 months from the date of delivery. If the Company were unable to take delivery of a previously ordered vehicle, the Company may incur nominal fees.

**Indemnifications**—In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred any cost to defend lawsuits or settle claims related to these indemnification provisions.

**Legal**—During the normal course of business, the Company may be a party to legal claims that may not be covered by insurance.

In March 2025, the United States District Court for the District Court of Massachusetts dismissed, without prejudice and without leave to amend, a putative class action complaint that was filed in August 2023 against the Company and certain current and former executive officers of the Company, which alleged, among other things, that the defendants violated Sections 10(b) and/or 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder by misrepresenting and/or omitting certain material facts related to the design of SYFOVRE's clinical trials and the risks associated with SYFOVRE's commercial adoption, and sought, among other relief, compensatory damages and equitable relief in favor of the alleged class against all defendants, including interest, and reasonable costs and expenses incurred by plaintiffs, including attorneys' and expert fees. In April 2025, the plaintiffs filed an appeal to the United States Court of Appeals for the First Circuit, where the case currently awaits further decision.

In December 2024, purported stockholders filed putative stockholder derivative lawsuits in the United States District Court for the District of Massachusetts on behalf of the Company against the Company's directors for breach of fiduciary duty, unjust enrichment, waste, and alleged violation of Section 14(a) of the Exchange Act related to the design of SYFOVRE's clinical trials and the risks associated with SYFOVRE's commercial adoption, and sought monetary and punitive damages, and costs, including attorneys' fees. These cases were consolidated under the caption *In re Apellis Pharmaceuticals, Inc. Derivative Litigation*, No. 1:24-cv-13128-JEK in January 2025 and are stayed pending the outcome of the appeal in the United States Court of Appeals for the First Circuit of the dismissal of the securities class action.

The Company's businesses may also be subject at any time to commercial disputes, product liability claims, personal injury claims, third-party subpoenas or various other lawsuits arising in the ordinary course of business, including intellectual property infringement, employment or investor matters, and the Company expects that this will continue to be the case in the future.

## **12. Net Income/(Loss) per Common Share**

Basic net income/(loss) per share is calculated by dividing the net income or loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net income/(loss) per share is computed by dividing the net income or loss by the weighted-average number of shares of common stock, plus potentially dilutive securities outstanding for the period, as determined in accordance with the treasury stock, if-converted, or contingently issuable accounting methods, depending on the nature of the security. For purposes of the diluted net income/(loss) per share calculation, stock options, restricted stock units ("RSUs"), shares potentially issuable in connection with the Company's employee stock purchase plan ("ESPP") and convertible notes are considered potentially dilutive securities and included to the extent that their addition is not antidilutive.

The following table presents the calculation of basic and diluted net income/(loss) per common share (amounts in thousands, except per share amounts):

[Table of Contents](#)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Basic net income/(loss) per share				
Numerator:				
Net income/(loss)	\$ 215,715	\$ (57,445)	\$ 81,339	\$ (161,525)
Denominator:				
Weighted-average number of common shares used in net income/(loss) per common share - basic	126,424	124,234	125,971	123,698
Net income/(loss) per common share - basic	<u>\$ 1.71</u>	<u>\$ (0.46)</u>	<u>\$ 0.65</u>	<u>\$ (1.31)</u>
Diluted net income/(loss) per share				
Numerator:				
Net income/(loss)	\$ 215,715	\$ (57,445)	\$ 81,339	\$ (161,525)
Adjustment - Interest expense on Convertible Notes	903	—	2,704	—
Adjusted net income/(loss)	\$ 216,618	\$ (57,445)	\$ 84,043	\$ (161,525)
Denominator:				
Weighted-average number of common shares used in net income/(loss) per common share - basic	126,424	124,234	125,971	123,698
Convertible notes	2,379	—	2,379	—
Stock options to purchase common stock	899	—	994	—
Unvested restricted stock units	350	—	287	—
Shares expected to be purchased under employee stock purchase plan	15	—	22	—
Weighted-average number of common shares used in net income/(loss) per common share - diluted	130,067	124,234	129,653	123,698
Net income/(loss) per common share - diluted	<u>\$ 1.67</u>	<u>\$ (0.46)</u>	<u>\$ 0.65</u>	<u>\$ (1.31)</u>

The following table presents securities excluded from the calculation of diluted net income/(loss) per share due to their anti-dilutive effect (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Convertible notes	—	2,379	—	2,379
Stock options to purchase common stock	7,230	8,063	6,284	8,063
Unvested restricted stock units	3,942	4,017	4,328	4,017
Total	<u>11,172</u>	<u>14,459</u>	<u>10,612</u>	<u>14,459</u>

### 13. Segment Information

The Company operates as a single operating segment, which is the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system. The Company defines its segment on the basis in which internally reported financial information is regularly reviewed by the chief operating decision maker ("CODM") to analyze financial performance, make decisions, and allocate resources. The CODM is the chief executive officer ("CEO"). The Company's CODM reviews consolidated net income/(loss) for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

The following table presents information about reported segment revenue, segment income/(loss), and significant segment expenses as provided to the CODM with respect to the Company's single operating segment for the three and nine months ended September 30, 2025 and 2024:

[Table of Contents](#)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2025	2024	2025	2024
Revenue	\$ 458,578	\$ 196,830	\$ 803,869	\$ 568,839
Less:				
Internal research and development costs	19,225	20,217	63,867	61,084
Internal selling, general and administrative costs	44,938	42,814	135,133	132,942
External commercial costs	59,690	55,392	176,764	173,271
External research and development costs	36,982	56,499	122,573	150,653
External general and administrative costs	21,842	8,154	43,689	25,022
Other segment items (1)	24,495	33,489	72,499	79,222
Share-based compensation expense	28,186	27,475	82,757	87,814
Interest income	(4,376)	(2,889)	(9,641)	(9,377)
Interest expense	11,279	12,532	33,480	28,857
Income tax expense	602	592	1,409	876
Net income/(loss)	\$ 215,715	\$ (57,445)	\$ 81,339	\$ (161,525)

(1) Other segment items include cost of sales and other expenses.

## **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and related notes for the year ended December 31, 2024 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2025, which we refer to as the 2024 Annual Report on Form 10-K.*

*This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.*

*We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Please also refer to those factors described in “Part I, Item 1A. Risk Factors” of our 2024 Annual Report on Form 10-K for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements.*

### **Overview**

We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system. We believe this approach has the potential to effectively control diseases with high unmet need that are driven by excessive complement activation. We currently have two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection), approved by the U.S. Food and Drug Administration, or FDA, in February 2023 for the treatment of geographic atrophy secondary to age-related macular degeneration, or GA; and EMPAVELI (pegcetacoplan), approved by the FDA in May 2021 for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH and in July 2025 for the treatment of C3 glomerulopathy, or C3G, and primary immune complex membranoproliferative glomerulonephritis, or IC-MPGN.

We believe SYFOVRE has the potential to be the standard of care for patients with GA, a disease that affects an estimated 1.5 million people in the United States. While we have exclusive, worldwide commercialization rights for intravitreal pegcetacoplan, we intend to focus our commercialization efforts in the U.S. and explore international expansion in select markets, including Australia, where we received marketing approval in January 2025. We launched SYFOVRE in the United States in March 2023. For the three months ended September 30, 2025 and 2024, we generated \$150.9 million and \$152.0 million, respectively, in U.S. net product revenue from sales of SYFOVRE. For the nine months ended September 30, 2025 and 2024, we generated \$431.7 million and \$444.0 million, respectively, in U.S. net product revenue from sales of SYFOVRE. We are also developing a next-generation therapy by combining SYFOVRE treatment with APL-3007, which is a small interfering RNA, or siRNA, aimed at comprehensively blocking complement activity in the retina and the choroid. We initiated a Phase 2 multi-dose trial with this therapy in patients with GA in June 2025.

We believe that EMPAVELI has the potential to be a best-in-class treatment for a range of indications with high unmet needs. We have exclusive U.S. commercialization rights for EMPAVELI. For the three months ended September 30, 2025 and 2024, we generated \$26.8 million and \$24.6 million, respectively, in U.S. net product revenue from sales of EMPAVELI. For the nine months ended September 30, 2025 and 2024, we generated \$67.3 million and \$74.7 million, respectively, in U.S. net product revenue from sales of EMPAVELI. In July 2025, the FDA approved EMPAVELI for the treatment of C3G and IC-MPGN, two nephrological conditions, which together affect an estimated 5,000 people in the United States. This approval was based on data from the VALIANT study, which demonstrated positive effects on the three key markers of disease at six months, including a 68% reduction in proteinuria in C3G and IC-MPGN patients compared to placebo ( $p < 0.0001$ ), the primary endpoint; stabilization of kidney function (nominal  $p=0.03$ ), as measured by estimated glomerular filtration rate, and a reduction in C3c staining intensity (nominal  $p<0.0001$ ) in a substantial proportion of patients. Data also demonstrated favorable safety and tolerability results, consistent with pegcetacoplan’s established profile. Results were consistent across all subgroups, including disease type, age, and transplant status.

Our collaboration partner, Swedish Orphan Biovitrum AB (Publ), or Sobi, has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan outside of the United States. For the three months ended September 30, 2025 and 2024, we received \$5.2 million and \$5.0 million, respectively, in royalties from our collaboration partner, Sobi, which has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan outside of the United States. For the nine months ended September 30, 2025 and 2024, we received \$12.6 million and \$13.9 million, respectively, in royalties from Sobi. On July 1, 2025, we entered into a Royalty Buy-Down Agreement (the “Royalty Agreement”) with Sobi under which Sobi paid us an upfront payment of \$275.0 million, and

## [Table of Contents](#)

agreed to pay up to an aggregate of \$25.0 million upon the European Medicines Agency ("EMA") approval of Aspaveli for C3G and IC-MPGN (collectively, the "purchase price"), and we agreed to reduce Sobi's royalty payment obligations under the Collaboration Agreement by 90%, subject to defined caps tied to Aspaveli's performance, including an initial cap of 1.45x of the purchase price. If a cap is met, Sobi's royalty payment obligations under the Collaboration Agreement will revert to 100%.

We expect to initiate two pivotal clinical trials with EMPAVELI by year-end 2025, one for the treatment of primary focal segmental glomerulosclerosis, or FSGS, and one for delayed graft function, or DGF. FSGS and DGF are both rare, severe nephrology conditions with no approved therapies in which complement overactivation plays a significant role.

Finally, we are developing new product candidates to further advance our pipeline. Through our collaboration with Beam Therapeutics, Inc., or Beam, we have commenced preclinical studies for a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing. We are also developing other programs outside of gene editing leveraging our proprietary in-house capabilities.

To date, we have financed our operations primarily through \$2.6 billion in net proceeds from public offerings of our common stock and pre-funded warrants to purchase common stock, \$414.1 million in payments and royalties from Sobi pursuant to our collaboration agreement, \$275.0 million from the royalty monetization, \$532.5 million under various credit arrangements, including with Sixth Street Lending Partners, or Sixth Street, and SFJ Pharmaceuticals Group, or SFJ, and \$98.8 million relating to the unwinding of certain capped call transactions in March 2024, as well as from the proceeds of our operations. To date, we have exchanged \$425.4 million and converted \$0.7 million of aggregate principal amount of our Convertible Notes (further discussed below) for shares of our common stock.

Excluding the net income generated from the Sobi Royalty Agreement for the three and nine months ended September 30, 2025, we have incurred significant net operating losses since inception, and expect to incur net operating losses in the current year. Our net income was \$215.7 million and \$81.3 million for the three and nine months ended September 30, 2025, compared to net losses of \$57.4 million and \$161.5 million for the three and nine months ended September 30, 2024. As of September 30, 2025, we had an accumulated deficit of \$3.0 billion.

Our operating results may fluctuate significantly from quarter to quarter and year to year. We anticipate that we will continue to incur significant commercialization expenses related to sales, marketing, medical affairs, manufacturing, distribution and other commercial infrastructure associated with the commercialization of EMPAVELI for the treatment of PNH and other indications and the commercialization of SYFOVRE for the treatment of GA. In addition, we expect to continue to incur these expenses if and as we continue to develop and conduct our ongoing and planned clinical trials of pegcetacoplan and our other product candidates; initiate and continue research and preclinical and clinical development efforts for any future product candidates; seek to identify and develop additional product candidates for complement-dependent diseases; seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any; establish sales, marketing, distribution and other commercial infrastructure to commercialize any additional products for which we may obtain marketing approval; require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization; maintain, expand and protect our intellectual property portfolio; hire and retain additional personnel, such as clinical, quality control, regulatory and scientific personnel; add operational, financial and management information systems and personnel, including personnel to support our product development and add equipment and physical infrastructure to support our research and development programs and commercialization.

### ***Financing Agreement and Credit Facility***

On May 13, 2024, we entered into a financing agreement, or the Sixth Street Financing Agreement, with certain of our material subsidiaries as guarantors party thereto, the lenders party thereto, or the Lenders, and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders.

The Sixth Street Financing Agreement provides for a senior secured term loan facility of up to \$475.0 million, or the Credit Facility, consisting of an initial draw of \$375.0 million at closing and a potential additional \$100.0 million draw at our option upon satisfaction of a \$50.0 million minimum cash requirement and a requirement that our trailing three-month sales of SYFOVRE is at least \$180.0 million prior to the \$100.0 million draw. The Company did not draw down the additional \$100.0 million and the option expired September 30, 2025.

The Credit Facility matures on May 13, 2030 (the "Maturity Date") and bears interest at an annual rate equal to 3-month Term SOFR (subject to 1.00% floor), plus 5.75%. Certain additional commitment and undrawn amount fees are also payable in connection with the Credit Facility.

The net proceeds from the initial draw of the Credit Facility were approximately \$358.2 million, net of \$16.8 million of issuance costs. We used the majority of the proceeds of the draw at closing to buy out our remaining obligations to SFJ, in the amount of approximately \$326.5 million.

## [Table of Contents](#)

The Credit Facility does not provide for scheduled amortization payments during the term. All principal will be due on the Maturity Date. We have the right to prepay loans under the Credit Facility at any time. We are required to repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. Repayments are subject to a prepayment premium. Repayments may be made after the first year of the loan and are subject to a prepayment premium up to 3% depending on timing.

On July 1, 2025, the lenders and Sixth Street Financing consented to the Royalty Agreement with Sobi (the "Consent"), and, in connection with that consent, we agreed to extend by one year from the effective date of the Consent the periods in which certain prepayment premiums would be owed under the Sixth Street Financing Agreement. This effectively extended the period the prepayment premium would be owed from one year after the date of the initial draw, or May 13, 2024, to one year after the effective date of the Consent, or July 1, 2025.

All obligations under the Sixth Street Financing Agreement are secured on a first-priority basis, subject to certain exceptions, by security interests in substantially all of our assets and assets of our material subsidiaries, including our intellectual property, and are guaranteed by our material subsidiaries, including foreign subsidiaries, subject to certain exceptions.

The Sixth Street Financing Agreement contains customary covenants, including, without limitation, a financial covenant to maintain liquidity of at least \$50.0 million if our market capitalization is below \$3.0 billion, and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, and other matters customarily restricted in such agreements. Among other permissions, we are permitted, on terms and conditions set forth on the Sixth Street Financing Agreement, to enter into a separate asset-based financing arrangement with a third party in an amount of up to \$100.0 million, which amount is increased to \$200.0 million upon certain sales or market capitalization thresholds, and to have outstanding convertible unsecured notes in an amount equal to the greater of \$400.0 million and 10% of our market capitalization, but not to exceed \$600.0 million. We are subject to restrictions on sales and licensing transactions with respect to our core intellectual property, defined to include SYFOVRE, EMPAVELI, and other pegcetacoplan product assets, subject to certain exceptions, including certain transactions related to areas outside the United States and Europe.

The Sixth Street Financing Agreement also contains certain events of default after which loans under the Credit Facility may be due and payable immediately, including payment defaults, material inaccuracy of representations and warranties, covenant defaults, bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against us and our subsidiaries, and change of control.

### ***Convertible Notes***

On September 16, 2019, we completed a private offering of convertible notes, or the 2019 Convertible Notes, with an aggregate principal amount of \$220.0 million issued pursuant to an indenture, or the Indenture, with U.S. Bank National Association, as trustee.

The net proceeds from the sale of the 2019 Convertible Notes were approximately \$212.9 million after deducting the initial purchasers' discounts and commissions of \$6.6 million and offering expenses of \$0.5 million. We used \$28.4 million of the net proceeds from the sale of the 2019 Convertible Notes to pay the cost of the capped call transactions in September 2019 described below.

On May 12, 2020, we issued convertible notes, or the 2020 Convertible Notes, with an aggregate principal amount of \$300.0 million. The net proceeds from the sale of the 2020 Convertible Notes were approximately \$322.9 million after deducting the purchasers' discounts and commission of \$5.7 million and offering expenses of \$0.3 million. We used \$43.1 million of the net proceeds from the sale to pay the cost of the additional capped call transactions in May 2020 described below.

The 2019 Convertible Notes and the 2020 Convertible Notes are referred to together as the Convertible Notes. The Convertible Notes are our senior unsecured obligations and bear interest at a rate of 3.5% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2020. The Convertible Notes will mature on September 15, 2026, unless converted earlier, redeemed or repurchased in accordance with their terms.

The Convertible Notes are convertible into shares of our common stock at an initial conversion rate of 25.3405 shares per \$1,000 principal amount of notes (equivalent to an initial conversion price of approximately \$39.4625 per share of common stock). The conversion rate is subject to customary anti-dilution adjustments. In addition, following certain events that occur prior to the maturity date or if we deliver a notice of redemption, we will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or a notice of redemption, as the case may be, in certain circumstances as provided in the Indenture.

## [Table of Contents](#)

Prior to March 15, 2026, the Convertible Notes are convertible only under the following circumstances:

- during any calendar quarter, if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
- during the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the Convertible Notes for each such trading day was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;
- if we call any or all of the Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or
- upon the occurrence of corporate events specified in the Indenture.

On, or after, March 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date of the Convertible Notes, holders may convert the Convertible Notes at any time regardless of the foregoing circumstances. Upon conversion of the Convertible Notes, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of common stock, at our election.

As of September 20, 2023, we may redeem for cash all or a portion of the Convertible Notes, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide a notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption. The redemption price will be equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If we call any Convertible Notes for redemption, it will constitute a “make-whole fundamental change” with respect to such Convertible Notes, in which case the conversion rate applicable to the conversion of such Notes, if converted in connection with the redemption, will be increased in certain circumstances. We have not called for redemption any of the Convertible Notes as of September 30, 2025.

If we undergo a “fundamental change,” as defined in the Indenture, prior to maturity, subject to certain conditions, holders may require us to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

In January 2021, July 2021 and July 2022, the Company entered into separate, privately negotiated exchange agreements to modify the conversion terms with certain holders of its 2019 Convertible Notes and 2020 Convertible Notes. Under the terms of these exchange agreements, in January 2021, July 2021 and July 2022, the holders exchanged approximately \$126.1 million of 2019 Convertible Notes, \$201.1 million of 2019 Convertible Notes and 2020 Convertible Notes, and \$98.1 million of 2020 Convertible Notes, respectively, in aggregate principal amount held by them for an aggregate of 3,906,869 shares, 5,992,217 shares and 3,027,018 shares, respectively, of common stock issued by the Company. The Company accounted for the conversion of the debt as an inducement by expensing the fair value of the shares that were issued in excess of the original terms of the Convertible Notes.

The conditional conversion feature of the Convertible Notes was not triggered as of September 30, 2025 and as of December 31, 2024.

As of September 30, 2025, we held in treasury Convertible Notes in principal amount of \$425.4 million which have not been cancelled.

### ***Collaboration Agreement with Sobi***

On October 27, 2020, we entered into the Sobi collaboration agreement, concerning the development and commercialization of pegcetacoplan and specified other structurally and functionally similar compstatin analogues or derivatives for use systemically or for local non-ophthalmological administration, collectively referred to as the licensed products. We granted Sobi an exclusive (subject to certain rights retained by us), sublicensable license of certain patent rights and know-how to develop and commercialize licensed products in all countries outside of the United States. Under the Sobi collaboration agreement, Sobi made an upfront payment of \$250.0 million in November 2020, and agreed to pay up to an aggregate of \$915.0 million upon the achievement of specified one-time regulatory and commercial milestone events, including a \$50.0 million milestone payable following the first regulatory and reimbursement approval of systemic pegcetacoplan in any major European country, and to reimburse us for up to \$80.0 million in development costs. Since contract inception, we have recognized \$65.0 million in contra-research and development expenses and waived the remaining \$15.0 million in connection with the decision to discontinue the CAD program.

## [Table of Contents](#)

The European Commission approved systemic Aspaveli (pegcetacoplan) for the treatment of adults with PNH in December 2021. In March 2022, we earned a \$50.0 million payment from Sobi related to the first regulatory and reimbursement milestone in Europe, which we received in April 2022. Up until June 30, 2025, we were also entitled to receive tiered, double-digit royalties (ranging from high teens to high twenties) on sales of licensed products outside of the United States, subject to customary deductions and third-party payment obligations, until the latest to occur of: (i) expiration of the last-to-expire of specified licensed patent rights; (ii) expiration of regulatory exclusivity; and (iii) ten (10) years after the first commercial sale of the applicable licensed product, in each case on a licensed product-by-licensed product and country-by-country basis. On July 1, 2025, we and certain of our subsidiaries entered into the Royalty Agreement, in which we agreed to reduce Sobi's royalty payment obligations under the Collaboration Agreement by 90%, effective as of July 1, 2025, subject to defined caps tied to Aspaveli's performance, including an initial cap of 1.45x the amounts paid by Sobi to us under the Royalty Agreement. If a cap is met, Sobi's royalty payment obligations under the Collaboration Agreement will revert to 100%. We remain responsible for our license fee obligations (including royalty obligations) to the University of Pennsylvania.

### **Financial Operations Overview**

#### ***Revenue***

Our revenues consist of product sales of EMPAVELI and SYFOVRE, and revenues derived from our collaboration agreement with Sobi.

Revenue is recognized when, or as, we satisfy a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. For performance obligations that are satisfied over time, we recognize revenue using an input or output measure of progress that best depicts the satisfaction of the relevant performance obligation.

#### ***Product Revenues***

Product revenue is derived from our sales of our commercial products, EMPAVELI and SYFOVRE, in the United States.

#### ***Licensing and Other Revenue***

Licensing and other revenue is derived from our collaboration agreement with Sobi concerning the development and commercialization of pegcetacoplan and specified other compstatin analogues or derivatives for use systemically or for local non-ophthalmic administration.

#### ***Cost of Sales***

Cost of sales consists primarily of costs associated with the manufacturing of EMPAVELI and SYFOVRE, product supplied to Sobi, and royalties owed to our licensor for such sales and certain period costs.

#### ***Research and Development Expenses***

Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:

- employee-related expenses including salaries, bonuses, benefits and share-based compensation expense related to individuals performing research and development activities;
- expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct clinical trials and research and development activities on our behalf, and contract manufacturing organizations that manufacture quantities of drug supplies for both our preclinical studies and clinical trials;
- the cost of consultants, including share-based compensation expense; and
- various other expenses incident to the management of our preclinical studies and clinical trials.

Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the

## [Table of Contents](#)

related goods are delivered or the services are performed. We have not provided program costs since inception because historically we have not tracked or recorded our research and development expenses on a program-by-program basis from inception.

The successful development of our product candidates in clinical development is highly uncertain. Accordingly, at this time, we cannot reasonably estimate the nature, timing and costs of the efforts that will be necessary to complete the remainder of the clinical development of these product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from pegcetacoplan in other jurisdictions and indications or any other potential product candidates. This is due to the numerous risks and uncertainties associated with developing therapeutics, including the uncertainties of:

- establishing an appropriate safety profile in preclinical studies;
- successful enrollment in, and completion of clinical trials;
- receipt of marketing approvals from applicable regulatory authorities;
- establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
- obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
- launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; and
- an acceptable safety profile of the products following approval.

A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase for the foreseeable future as our product candidate development programs progress. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.

### ***Selling, General and Administrative Expenses***

Selling, general and administrative expenses consist primarily of costs associated with the commercialization of approved products and general and administrative costs to support operations, including salaries, bonuses, benefits and share-based compensation. Selling expenses include product marketing, sales operations costs, and other costs incurred to support our sales efforts. General and administrative expenses include corporate support functions such as executive management, finance and accounting, business development, legal, human resources, information technology, and associated external costs to support those functions. Other significant costs include costs associated with medical affairs, drug safety and pharmacovigilance, quality and regulatory, costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services. Marketing and advertising costs include marketing literature, promotional activities, conferences and seminars, branding and sponsorships.

We anticipate that our selling, general and administrative expenses will increase in the future to support continued commercial activities for our approved products, potential commercialization of our product candidates and costs of operating as a public company.

### **Critical Accounting Estimates**

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reported periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to product revenue, inventory and accrued research and development expenses, which we described in our 2024 Annual Report on Form 10-K. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

[Table of Contents](#)

Our significant accounting policies are described in Note 2 of Part I, Item 1 of this Quarterly Report on Form 10-Q and in Part I, Item 7, “Critical Accounting Estimates” in our 2024 Annual Report on Form 10-K. There have been no changes to our critical accounting policies and estimates since our 2024 Annual Report on Form 10-K.

**Results of Operations**

*Three Months Ended September 30, 2025 and 2024 (in thousands, except percentages)*

	For the Three Months Ended September 30,		Change \$	Change %
	2025	2024		
<b>Revenue:</b>				
Product revenue, net	\$ 177,755	\$ 176,571	\$ 1,184	1%
Licensing and other revenue	280,823	20,259	260,564	1286%
Total revenue:	458,578	196,830	261,748	133%
<b>Operating expenses:</b>				
Cost of sales	24,531	33,557	(9,026)	(27%)
Research and development	68,186	88,569	(20,383)	(23%)
Selling, general and administrative	142,678	121,984	20,694	17%
Total operating expenses:	235,395	244,110	(8,715)	(4%)
Net operating income/(loss)	223,183	(47,280)	270,463	(572%)
Interest income	4,376	2,889	1,487	51%
Interest expense	(11,279)	(12,532)	1,253	(10%)
Other income, net	37	70	(33)	(47%)
Net income/(loss) before taxes	216,317	(56,853)	273,170	(480%)
Income tax expense	602	592	10	2%
Net income/(loss)	\$ 215,715	\$ (57,445)	\$ 273,160	(476%)

*Product Revenue, Net*

Our product revenue, net is derived from EMPAVELI and SYFOVRE sales in the United States. We recognized \$177.8 million and \$176.6 million of net product revenue for the three months ended September 30, 2025 and 2024, respectively. The net product revenue of \$177.8 million for the three months ended September 30, 2025 consists of \$26.8 million in net product revenue from sales of EMPAVELI and \$150.9 million in net product revenue from sales of SYFOVRE. The net product revenue of \$176.6 million for the three months ended September 30, 2024 consists of \$24.6 million in net product revenue from sales of EMPAVELI and \$152.0 million in net product revenue from sales of SYFOVRE. The decrease in net product revenue for SYFOVRE was primarily driven by increased rebates, partially offset by an increase in volume. The increase in net product revenue for EMPAVELI was primarily driven by an increase in volume.

*Licensing and Other Revenue*

Licensing and other revenue of \$280.8 million for the three months ended September 30, 2025 consisted of \$5.2 million in revenue from product supplied to Sobi, \$0.6 million in royalty revenue from Sobi and \$275.0 million from the Sobi Royalty Agreement. Licensing and other revenue of \$20.3 million for the three months ended September 30, 2024 consisted of \$15.3 million in revenue from product supplied to Sobi and \$5.0 million in royalty revenue from Sobi. The increase in licensing and other revenue was primarily driven by a \$275.0 million increase due to the upfront payment from Sobi under the Royalty Agreement, which was partially offset by a \$10.1 million decrease in product supplied to Sobi and a decrease in royalty revenue of \$4.3 million.

*Cost of Sales*

Cost of sales was \$24.5 million for the three months ended September 30, 2025 and \$33.6 million for the three months ended September 30, 2024. The decrease in cost of sales was primarily driven by a \$5.9 million decrease due to lower volumes of product supplied to Sobi, a \$0.8 million decrease in expenses incurred related to excess, obsolete or scrapped inventory, and a \$6.1 million decrease due to costs incurred in connection with cancellable purchase commitments. The decreases were partially offset by a \$3.5 million increase due to higher volume from commercial sales and product provided under our patient assistance programs.

In addition, prior to receiving FDA approval for EMPAVELI and SYFOVRE, the costs associated with the manufacturing of EMPAVELI and SYFOVRE inventory were expensed as incurred as research and development expense. This resulted in inventory being sold during the three months ended September 30, 2025 and 2024 for which a portion of the costs had previously been expensed prior to FDA approval. This did not materially impact cost of sales for the three months ended September 30, 2025 and 2024. We

[Table of Contents](#)

expect this may continue to impact the cost of sales and research and development expense as we continue to sell to customers or use the remaining pre-FDA approved inventory in preclinical or clinical studies. As of September 30, 2025 and December 31, 2024, the remaining pre-FDA approved inventory was \$18.1 million and \$19.5 million, respectively, which primarily consisted of raw materials and semi-finished goods.

*Research and Development Expenses*

The following table summarizes our research and development expenses incurred during the three months ended September 30, 2025 and 2024 (in thousands, except percentages):

(In thousands)	For the Three Months Ended September 30,		Change \$	Change %
	2025	2024		
<b>Program-specific external costs:</b>				
PNH	\$ 4,081	\$ 3,584	\$ 497	14%
C3G & IC-MPGN	3,471	7,715	(4,244)	(55%)
HSCT-TMA	513	989	(476)	(48%)
GA	15,242	14,610	632	4%
Other development and discovery programs (1)	13,114	18,726	(5,612)	(30%)
<b>Total program-specific costs</b>	<b>36,421</b>	<b>45,624</b>	<b>(9,203)</b>	<b>(20%)</b>
<b>Unallocated external costs</b>				
Non-program specific external costs	562	10,875	(10,313)	(95%)
<b>Total unallocated external costs</b>	<b>562</b>	<b>10,875</b>	<b>(10,313)</b>	<b>(95%)</b>
<b>Unallocated internal costs</b>				
Compensation and related personnel costs	29,803	30,886	(1,083)	(4%)
Other expenses	1,400	1,184	216	18%
<b>Total unallocated internal costs</b>	<b>31,203</b>	<b>32,070</b>	<b>(867)</b>	<b>(3%)</b>
<b>Total research and development costs</b>	<b>\$ 68,186</b>	<b>\$ 88,569</b>	<b>\$ (20,383)</b>	<b>(23%)</b>

(1) Includes discontinued clinical activities related to the ALS and CAD programs, amounting to \$1.9 million for the three months ended September 30, 2024.

Research and development expenses decreased by \$20.4 million to \$68.2 million for the three months ended September 30, 2025 from \$88.6 million for the three months ended September 30, 2024, a decrease of 23%. The decrease in research and development expenses was primarily attributable to a \$9.2 million decrease in program specific external costs, a \$10.3 million decrease in non-program specific external costs and a \$1.1 million decrease in compensation and related personnel costs, which was partially offset by an increase of \$0.2 million in other expenses.

The decrease in our program-specific external costs of \$9.2 million was driven by a \$4.2 million decrease in C3G & IC-MPGN costs due to lower costs related to the VALIANT study, and a \$5.6 million decrease in other development and discovery costs primarily due to a decrease of \$1.7 million in our previously announced discontinuation of the CAD program and a decrease of \$3.7 million other development and discovery costs. These decreases were partially offset by an increase of \$0.6 million in GA costs associated with the product lifecycle development and an increase of \$0.5 million in PNH costs due to higher activity related to post trial access programs.

The decrease in compensation and related personnel costs was driven by a decrease of \$0.4 million in salaries and benefits and a decrease of \$0.7 million in share-based compensation expense.

*Selling, General and Administrative Expenses*

Selling, general and administrative expenses increased by \$20.7 million to \$142.7 million for the three months ended September 30, 2025, from \$122.0 million for the three months ended September 30, 2024, an increase of 17%. The increase was primarily attributable to an increase of \$2.9 million in general commercial activities, an increase of \$2.2 million in personnel costs and a \$16.3 million increase in general and administrative expenses, including office expenses, travel expenses, insurance expenses, professional and consulting fees, and other general and administrative expenses which was partially offset by a decrease of \$0.7 million in factoring fees. The increase in personnel related costs of \$2.2 million consisted of a \$1.1 million increase in salaries and benefits and an increase of \$1.1 million in share-based compensation expense.

[Table of Contents](#)

*Interest Income*

Interest income was \$4.4 million for the three months ended September 30, 2025, an increase of \$1.5 million compared to \$2.9 million for the three months ended September 30, 2024. The increase in interest income was primarily attributable to increased investments during the three months ended September 30, 2025.

*Interest Expense*

Interest expense was \$11.3 million for the three months ended September 30, 2025, a decrease of \$1.3 million, compared to \$12.5 million for the three months ended September 30, 2024. The decrease is primarily due to a decrease in interest incurred under the Credit Facility.

*Nine Months Ended September 30, 2025 and 2024 (in thousands, except percentages)*

	For the Nine Months Ended September 30,		Change \$	Change %
	2025	2024		
<b>Revenue:</b>				
Product revenue, net	\$ 499,042	\$ 518,782	\$ (19,740)	(4%)
Licensing and other revenue	304,827	50,057	254,770	509%
Total revenue:	803,869	568,839	235,030	41%
<b>Operating expenses:</b>				
Cost of sales	72,517	76,867	(4,350)	(6%)
Research and development	221,621	251,216	(29,595)	(12%)
Selling, general and administrative	403,162	379,571	23,591	6%
Total operating expenses:	697,300	707,654	(10,354)	(1%)
Net operating income/(loss)	106,569	(138,815)	245,384	(177%)
Loss on extinguishment of development liability	—	(1,949)	1,949	(100%)
Interest income	9,641	9,377	264	3%
Interest expense	(33,480)	(28,857)	(4,623)	16%
Other expense, net	18	(405)	423	(104%)
Net income/(loss) before taxes	82,748	(160,649)	243,397	(152%)
Income tax expense	1,409	876	533	61%
Net income/(loss)	<u>\$ 81,339</u>	<u>\$ (161,525)</u>	<u>\$ 242,864</u>	<u>(150%)</u>

*Product Revenue, Net*

Our product revenue, net is derived from EMPAVELI and SYFOVRE sales in the United States. We recognized \$499.0 million and \$518.8 million of net product revenue for the nine months ended September 30, 2025 and 2024, respectively. The net product revenue of \$499.0 million for the nine months ended September 30, 2025, consisted of \$67.3 million in net product revenue from sales of EMPAVELI and \$431.7 million in net product revenue from sales of SYFOVRE. The net product revenue of \$518.8 million for the nine months ended September 30, 2024, consisted of \$74.7 million in net product revenue from sales of EMPAVELI and \$444.0 million in net product revenue from sales of SYFOVRE. The decrease in net product revenue for SYFOVRE was primarily driven by increased rebates, partially offset by an increase in volume. The decrease in net product revenue for EMPAVELI was primarily driven by increased competitive pressure from the availability of oral products.

*Licensing and Other Revenue*

Licensing and other revenue of \$304.8 million during the nine months ended September 30, 2025 consisted of \$17.2 million in revenue for product supplied to Sobi and \$12.6 million in royalty revenue from Sobi and \$275.0 million from the Sobi Royalty Agreement. Licensing and other revenue of \$50.1 million during the nine months ended September 30, 2024 consisted of \$36.2 million in revenue for product supplied to Sobi and \$13.9 million in royalty revenue from Sobi. The increase in licensing and other revenue was primarily driven by an increase of \$275.0 million due to the upfront payment from Sobi under the Royalty Agreement, which was partially offset by a decrease in product supplied to Sobi of \$19.0 million and a decrease in royalty revenue of \$1.3 million.

*Cost of Sales*

Cost of sales was \$72.5 million for the nine months ended September 30, 2025 and \$76.9 million for the nine months ended September 30, 2024. The decrease in cost of sales was primarily driven by an \$8.1 million decrease due to lower volume of product supplied to Sobi and a decrease of \$3.4 million due to costs incurred in connection with cancellable purchase commitments. The decreases were partially offset by an increase of \$6.7 million due to higher volumes from commercial sales and product provided under our patient assistance programs and an increase of \$0.3 million in expenses incurred related to excess, obsolete or scrapped inventory.

[Table of Contents](#)

In addition, prior to receiving FDA approval for EMPAVELI and SYFOVRE, the costs associated with the manufacturing of EMPAVELI and SYFOVRE inventory were expensed as incurred as research and development expense. This resulted in inventory being sold during the nine months ended September 30, 2025 and 2024 for which a portion of the costs had previously been expensed prior to FDA approval. This did not materially impact cost of sales for the nine months ended September 30, 2025 and 2024. We expect this may continue to impact the cost of sales and research and development expense as we continue to sell to customers or use the remaining pre-FDA approved inventory in preclinical or clinical studies. As of September 30, 2025 and December 31, 2024, the remaining pre-FDA approved inventory was \$18.1 million and \$19.5 million, respectively, which primarily consisted of raw materials and semi-finished goods.

*Research and Development Expenses*

The following table summarizes our research and development expenses incurred during the nine months ended September 30, 2025 and 2024 (in thousands, except percentages):

	For the Nine Months Ended September 30,		Change \$	Change %
	2025	2024		
<b>Program-specific external costs:</b>				
PNH	\$ 7,128	\$ 13,412	\$ (6,284)	(47%)
C3G & IC-MPGN	17,084	26,431	(9,347)	(35%)
HSCT-TMA	1,750	2,024	(274)	(14%)
GA	44,790	35,801	8,989	25%
Other development and discovery programs (1)	48,221	60,020	(11,799)	(20%)
<b>Total program-specific costs</b>	<b>118,973</b>	<b>137,688</b>	<b>(18,715)</b>	<b>(14%)</b>
<b>Unallocated external costs</b>				
Non-program specific external costs	3,599	12,967	(9,368)	(72%)
<b>Total unallocated external costs</b>	<b>3,599</b>	<b>12,967</b>	<b>(9,368)</b>	<b>(72%)</b>
<b>Unallocated internal costs</b>				
Compensation and related personnel costs	95,058	96,720	(1,662)	(2%)
Other expenses	3,991	3,841	150	4%
<b>Total unallocated internal costs</b>	<b>99,049</b>	<b>100,561</b>	<b>(1,512)</b>	<b>(2%)</b>
<b>Total research and development costs</b>	<b>\$ 221,621</b>	<b>\$ 251,216</b>	<b>\$ (29,595)</b>	<b>(12%)</b>

(1) Includes discontinued clinical activities related to the ALS and CAD programs, amounting to \$1.1 million and \$20.2 million for the nine months ended September 30, 2025 and 2024, respectively.

Research and development expenses decreased by \$29.6 million to \$221.6 million for the nine months ended September 30, 2025 from \$251.2 million for the nine months ended September 30, 2024, a decrease of 12%. The decrease in research and development expenses was primarily attributable to an \$18.7 million decrease in program-specific external costs, a \$9.3 million decrease in non-program specific external costs and a decrease of \$1.6 million in compensation and related personnel costs.

The decrease in our program-specific external costs of \$18.7 million was driven by a \$6.2 million decrease in PNH costs due to lower costs incurred relating to clinical activities, a \$9.3 million decrease in C3G & IC-MPGN costs due to lower costs related to the VALIANT study, and a \$11.8 million decrease in other development and discovery costs primarily due to a decrease of \$19.1 million in previously announced discontinuation of the ALS and CAD programs, which were partially offset by an increase of \$7.3 million in other development and discovery costs primarily attributable to our efforts on the Beam FcRn collaboration. These decreases were partially offset by an increase of \$9.0 million in GA costs associated with the product lifecycle development.

The decrease in compensation and related personnel costs was driven by a decrease of \$4.6 million in share-based compensation expense, which was partially offset by \$3.0 million in salaries and benefits.

*Selling, General and Administrative Expenses*

Selling, general and administrative expenses increased by \$23.6 million to \$403.2 million for the nine months ended September 30, 2025, from \$379.6 million for the nine months ended September 30, 2024, an increase of 6%. The increase was primarily attributable to an increase of \$5.7 million in professional and consulting fees, an increase of \$0.6 million in personnel cost, an increase of \$1.8 million in factoring fees and a \$15.5 million increase in general and administrative expenses, including office expenses, travel expenses, insurance expenses, and other general and administrative expenses. The increase in personnel related costs of \$0.6 million consisted of a \$1.4 million increase in salaries and benefits, an increase of \$0.7 million in recruitment expenses, and partially offset by a \$1.5 million decrease in share-based compensation expense.

## [Table of Contents](#)

### *Loss on extinguishment of development liability*

We paid our remaining obligations under the SFJ agreement in May 2024. We concluded that the development liability was extinguished as of the payoff date. The difference of \$1.9 million between the reacquisition price of \$326.5 million and the net carrying value of the development liability of \$324.6 million was recorded as a loss on the extinguishment of the development liability as of September 30, 2024.

### *Interest Income*

Interest income was \$9.6 million for the nine months ended September 30, 2025, an increase of \$0.3 million compared to \$9.4 million for the nine months ended September 30, 2024. The increase in interest income was primarily attributable to increased investments during the nine months ended September 30, 2025.

### *Interest Expense*

Interest expense was \$33.5 million for the nine months ended September 30, 2025, an increase of \$4.6 million compared to \$28.9 million for the nine months ended September 30, 2024. The increase is primarily due to the interest incurred under the Credit Facility given the Credit Facility commenced May 2024.

### *Income Tax Expense*

Income tax expense was \$1.4 million for the nine months ended September 30, 2025, an increase of \$0.5 million, compared to \$0.9 million for the nine months ended September 30, 2024. The increase primarily pertained to an increase in state taxes.

## **Liquidity and Capital Resources**

### *Sources of Liquidity*

To date, we have financed our operations primarily through approximately \$2.6 billion in net proceeds from public and private offerings of our common stock and convertible securities, \$414.1 million in payments and royalties from Sobi pursuant to our collaboration agreement, \$275.0 million from the royalty monetization, \$532.5 million under various credit arrangements, including with Sixth Street and SFJ, and \$98.8 million relating to the unwinding of the capped call transactions in March 2024, as well as from the proceeds of our operations.

In May 2024, we entered into the Sixth Street Financing Agreement, which provides for the Credit Facility, consisting of an initial draw of \$375.0 million at closing and a potential additional \$100.0 million draw at our option upon satisfaction of a \$50.0 million minimum cash requirement and a requirement that our trailing three-month sales of SYFOVRE is at least \$180.0 million prior to the \$100.0 million draw. The Credit Facility matures on May 13, 2030 and bears interest at an annual rate equal to the 3-month Secured Overnight Financing Rate (SOFR) + 5.75% (subject to 1.00% floor). Certain additional commitment and undrawn amount fees are also payable in connection with the Credit Facility. We used the majority of the proceeds of the \$375.0 million draw at closing to buy out our remaining obligations owed to SFJ, in the amount of approximately \$326.5 million.

We are permitted under the Sixth Street Financing Agreement to enter into a separate asset-based financing arrangement with a third party in an amount of up to \$100.0 million, which amount is increased to \$200.0 million upon certain sales or market capitalization thresholds, and to have outstanding convertible unsecured notes in an amount equal to the greater of \$400.0 million and 10% of our market capitalization, but not to exceed \$600.0 million.

In August 2024, the Company entered into an agreement (the "Factoring Agreement") to sell certain accounts receivable to a third-party financial institution at a discount to the face value of the accounts receivable. Under the Factoring Agreement, the maximum amount of outstanding accounts receivables sold at any time is \$100.0 million. The accounts receivable sold that remained outstanding as of September 30, 2025 and December 31, 2024 was zero and \$86.1 million, respectively.

In November 2023, we entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, as agent, pursuant to which we may offer and sell shares of our common stock having an aggregate offering from of up to \$300.0 million from time to time. Any sales made under the sales agreement will be made at market prices by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933. Any sales under the sales agreement will be made pursuant to our registration statement on Form S-3, which became effective on February 22, 2023. We agreed to pay Cowen compensation of up to 3.0% of the gross proceeds of the sale of shares made under the sales agreement. We did not make any sales under the sales agreement during the nine months ended September 30, 2025.

In February 2023, we issued and sold 4,007,936 shares of our common stock and, in lieu of common stock to investors who so chose, pre-funded warrants to purchase 2,380,956 shares of our common stock in a follow-on offering, including 833,333 shares sold

[Table of Contents](#)

pursuant to the underwriters' exercise in full of their option to purchase additional shares of common stock. The price to the public of the shares of common stock was \$63.00 per share and the price to the public of the pre-funded warrants was \$62.9999 per pre-funded warrant. The pre-funded warrants have an exercise price equal to \$0.0001 per share and do not expire. The pre-funded warrants were accounted for as equity instruments. We received total net proceeds of \$384.4 million, after deducting underwriting discounts and commissions of \$18.8 million and offering cost of \$0.3 million. As of September 30, 2025, pre-funded warrants to purchase 80,965 shares of our common stock were still outstanding.

In February 2024, we entered into agreements with the capped call counterparties to unwind a portion of the capped call transactions. The unwind agreements applied to the portion of the capped call transactions in a notional amount corresponding to the \$426.1 million principal amount of Convertible Notes that we held in treasury as of December 31, 2024 or have been previously converted. The unwind transactions were settled at volume-weighted average price per share of \$64.11, which resulted in cash proceeds to us of \$98.8 million. As of September 30, 2025, the remaining capped call transactions had a notional amount corresponding to \$93.9 million principal amount of Convertible Notes.

### Cash Flows

The following table provides information regarding our cash flows for the nine months ended September 30, 2025 and 2024 (in thousands):

	For the Nine Months Ended September 30,	
	2025	2024
Net cash provided by/(used in) operating activities	\$ 59,503	\$ (107,226)
Net cash used in investing activities	(205)	(383)
Net cash provided by financing activities	7,625	153,241
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1,066	306
Net increase in cash, cash equivalents and restricted cash	\$ 67,989	\$ 45,938

#### Net Cash Provided by/(Used in) Operating Activities

Net cash provided by operating activities was \$59.5 million for the nine months ended September 30, 2025 and consisted primarily of a net income of \$81.3 million, adjusted for \$85.8 million of non-cash items, including share-based compensation expense of \$82.8 million, depreciation expense of \$1.2 million and amortization of discounts for credit facility of \$1.6 million. Further, it included a net increase in operating assets and liabilities of \$107.7 million, which was driven by an increase in accounts receivable of \$80.6 million, an increase in inventory of \$6.6 million, an increase in prepaid assets of \$13.2 million, a decrease in other current assets of \$1.6 million, an increase in other assets of \$4.2 million, a decrease in accrued expenses of \$0.2 million, and a decrease of \$4.7 million in other liabilities. The change in accounts receivable was primarily driven by a reduction in the derecognition of certain accounts receivable under our Factoring Agreement.

Net cash used in operating activities was \$107.2 million for nine months ended September 30, 2024 and consisted primarily of a net loss of \$161.5 million, adjusted for \$101.0 million of non-cash items, including share-based compensation expense of \$87.8 million, depreciation expense of \$1.4 million, a loss on the extinguishment of development liability of \$1.9 million and accretion of discount to the development liability of \$8.9 million. Further, it included a net increase in operating assets and liabilities of \$46.7 million, which was driven by an increase in accounts receivable of \$72.6 million, an increase in inventory of \$20.8 million, a decrease in prepaid assets of \$15.2 million, a decrease in other current assets of \$10.7 million, a decrease in accounts payable of \$0.4 million, an increase in accrued expenses of \$12.1 million, an increase in other liabilities of \$7.5 million, and an increase in deferred revenue of \$1.9 million. The increase in accounts receivable was reduced by the transfer of \$56.6 million of accounts receivable during the nine months ended September 30, 2024 to CITIBANK N.A. ("Citi") under the factoring agreement entered into on August 5, 2024.

#### Net Cash Provided by Financing Activities

Net cash provided by financing activities was \$7.6 million during the nine months ended September 30, 2025 and consisted primarily of proceeds from the exercise of stock options and proceeds from the employee stock purchase plan.

Net cash provided by financing activities was \$153.2 million during the nine months ended September 30, 2024 and consisted primarily of net proceeds from the initial draw of the Credit Facility of \$363.9 million, the settlement of capped call unwind transactions of \$98.8 million, \$14.0 million of proceeds from the exercise of stock options and \$3.2 million proceeds from the issuance of our common stock under the employee stock purchase plan partially offset by repayment of \$326.5 million for the development liability.

## ***Funding Requirements***

We expect to continue to incur expenses to support our ongoing commercial activities related to product manufacturing, marketing, sales and distribution of EMPAVELI for PNH, C3G and IC-MPGN and SYFOVRE for GA. In addition, we expect to continue to incur expenses as we prioritize the ongoing development of systemic pegcetacoplan and focus our research initiatives on high potential opportunities.

Together with the cash that we anticipate will be generated from sales of EMPAVELI and SYFOVRE, we expect that our current cash and cash equivalents will be sufficient to fund our projected operating expenses and capital expenditure requirements for at least the next 12 months, as well as our anticipated longer-term cash requirements and obligations. Our expectations regarding our short-term and long-term funding requirements are based on assumptions that may prove to be wrong, and we may need additional capital resources to fund our operating plans and capital expenditure requirements.

We are devoting substantial resources to the commercial infrastructure for SYFOVRE for GA. We are also devoting substantial resources to the development of our product candidates. Because of the numerous risks and uncertainties associated with the commercialization of EMPAVELI and SYFOVRE and development of other product candidates, and because the extent to which we may enter into collaborations with third parties for any of these activities is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with the research, development and commercialization. Our future funding requirements and long-term capital requirements will depend on many factors, including:

- our ability to continue to successfully commercialize and sell EMPAVELI and SYFOVRE in the United States;
- the cost of and our ability to obtain regulatory approvals of SYFOVRE outside of the United States and continue to build a commercial infrastructure for SYFOVRE for GA in the United States and worldwide;
- the cost of and our ability to effectively establish and maintain, the commercial infrastructure and manufacturing capabilities required to support the continued commercialization of EMPAVELI, systemic pegcetacoplan and SYFOVRE and any other products for which we receive marketing approval including product sales, medical affairs, marketing, manufacturing and distribution;
- the scope, progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for systemic pegcetacoplan, SYFOVRE and our other product candidates;
- our ability to maintain a productive collaborative relationship with Sobi with respect to systemic pegcetacoplan, including our ability to achieve milestone payments under our agreement with Sobi;
- our ability to identify additional collaborators for any of our product candidates and the terms and timing of any collaboration agreement that we may establish for the development and any commercialization of such product candidates;
- the number and characteristics of future product candidates that we pursue and their development requirements;
- the outcome, timing and costs of clinical trials and of seeking regulatory approvals of pegcetacoplan in other jurisdictions and indications and other product candidates we may pursue;
- the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not the responsibility of any collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
- subject to receipt of marketing approval, revenue, if any, received from commercial sales of pegcetacoplan in other jurisdictions and indications and our other product candidates;
- our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
- the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;
- the effect of competing technological and market developments;
- the effect of public health crises, including pandemics and epidemics, on the healthcare system and the economy generally and on our clinical trials and other operations specifically;
- our ability to obtain adequate reimbursement for EMPAVELI and SYFOVRE in the United States or any other product we commercialize; and
- the costs of operating as a public company.

[Table of Contents](#)

If our cash and cash equivalents, and cash generated from sales of EMPAVELI and SYFOVRE are not sufficient to fund our planned expenditures, we will need to finance our cash needs through external sources of funds, which may include equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements. We currently do not have any committed external source of funds.

If we are unable to generate sufficient funds from sales of EMPAVELI and SYFOVRE, or raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

### ***Contractual Obligations***

The disclosure of our contractual obligations and commitments is set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Contractual Obligations” in our 2024 Annual Report on Form 10-K. See Note 11. Commitments and Contingencies in the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item I of this Form 10-Q for a discussion of obligations and commitments.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

We are exposed to market risk related to changes in interest rates. As of September 30, 2025, we had cash and cash equivalents of \$479.2 million, inclusive of money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and cash equivalents, and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio.

### **Item 4. Controls and Procedures.**

#### **Limitations on Effectiveness of Controls and Procedures**

The term “disclosure controls and procedures,” as defined in Rules 13a-15(f) and 15d-15(e) under the Exchange Act of 1934 as amended, or the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

#### **Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2025.

#### **Changes in Internal Control Over Financial Reporting**

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II—OTHER INFORMATION****Item 1. Legal Proceedings**

See Note 11. Commitments and Contingencies in the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item I of this Form 10-Q.

**Item 1A. Risk Factors.**

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, which could materially affect our business, financial condition or future results. The risk factors disclosure in our Annual Report on Form 10-K for the year ended December 31, 2024 is qualified by the information that is described in this Quarterly Report on Form 10-Q. The risks described in our Annual Report on Form 10-K for the year ended December 31, 2024 are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

**Item 5. Other Information.**

The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):

<b>Name (Title)</b>	<b>Action Taken (Date of Action)</b>	<b>Type of Trading Arrangement</b>	<b>Nature of Trading Arrangement</b>	<b>Duration of Trading Arrangement</b>	<b>Aggregate Number of Securities</b>
Cedric G Francois President and Chief Executive Officer	Termination 8/14/2025	Rule 10b5-1 trading arrangement	Sale	(1)	(1)
Caroline Bauml Chief Medical Officer	Adoption 8/19/2025	Rule 10b5-1 trading arrangement	Sale	Until 2/27/2027, or such earlier date upon which all transactions are completed or expire without execution	Up to 14,698 shares
James Chopas Vice President, Corporate Controller and Chief Accounting Officer	Adoption 9/15/2025	Rule 10b5-1 trading arrangement	Sale	Until 1/29/2027, or such earlier date upon which all transactions are completed or expire without execution	Up to 25,947 shares

(1) This trading plan related to 358,090 shares of our common stock and had a scheduled expiration date of 7/31/2025.

[Table of Contents](#)

**Item 6. Exhibits.**

<b>Exhibit Number</b>	<b>Description</b>
10.1††*	<a href="#">Royalty Buy-Down Agreement dated July 1, 2025, by and between Swedish Orphan Biovitrum AB and the Registrant.</a>
31.1*	<a href="#">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2*	<a href="#">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1*	<a href="#">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
32.2*	<a href="#">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

\* Filed herewith.

†† Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Apellis Pharmaceuticals, Inc.

Date: October 30, 2025

By: /s/ Cedric Francois  
Cedric Francois  
President and Chief Executive Officer  
(principal executive officer)

Date: October 30, 2025

By: /s/ Timothy Sullivan  
Timothy Sullivan  
Chief Financial Officer and Treasurer  
(principal financial officer)

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

## ROYALTY BUY-DOWN AGREEMENT

This ROYALTY BUY-DOWN AGREEMENT (“**Agreement**”) is made as of July 1, 2025 (the “**Effective Date**”) by and among Apellis International GmbH, f/k/a Apellis Switzerland GmbH, a company with limited liability (*Gesellschaft mit beschränkter Haftung*) registered under the laws of Switzerland and having its registered office at Zählerweg 10, 6300 Zug, Switzerland (“**Apellis GmbH**”), Apellis Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 100 5th Avenue, Waltham, MA 02451 USA (“**Apellis US**”) and APL DEL Holdings, LLC, a company organized and existing under the laws of Delaware with its registered agent located at c/o Vcorp Services, LLC, 1013 Centre Road, Suite 403-B, in the City of Wilmington, County of New Castle, Delaware, 19805 (“**Apellis LLC**”) (Apellis GmbH, Apellis US and Apellis LLC together referred to as “**Apellis**”) and Swedish Orphan Biovitrum AB (publ), a Swedish public company having its principal place of business at SE-112 76 Stockholm, Sweden (“**Sobi**”). Apellis and Sobi are each referred to herein individually as “**Party**” and collectively “**Parties**”. Capitalized terms used herein and not defined herein shall have the meanings ascribed to them in the Collaboration and License Agreement dated as of October 27, 2020 by and among the Parties (the “**CLA**”).

### RECITALS

**WHEREAS**, under the CLA, the Parties have agreed to collaborate to develop and commercialize the compound known as APL-2 in certain indications;

**WHEREAS**, the Parties now desire to enter into this Agreement, pursuant to which Sobi will make certain payment(s) to Apellis in consideration for Apellis reducing Sobi’s royalty obligations with respect to Net Sales of Products in the Sobi Territory for a specified period of time; and

**WHEREAS**, the Parties also desire to memorialize certain agreements between them with respect to Apellis’ conduct of certain Clinical Trials in the Sobi Territory;

**NOW THEREFORE**, in consideration of the mutual covenants set out below, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

### ARTICLE 1 ROYALTY BUY-DOWN

1.1 **Purchase Price.** Solely in consideration for the modifications to Sobi’s royalty obligations set forth in Section 1.2 below, Sobi shall make the following one-time payments to Apellis:

- (a) Within five (5) business days following the Effective Date, Sobi shall pay Apellis two hundred seventy-five million Dollars (\$275,000,000).
-

- (b) Within [\*\*] after receipt of Regulatory Approval of a Product from the EMA for the treatment of C3G or a substantially similar Indication, Sobi shall pay Apellis [\*\*] Dollars (\$[\*\*]).
- (c) Within [\*\*] after receipt of Regulatory Approval of a Product from the EMA for the treatment of primary immune complex membranoproliferative glomerulonephritis or a substantially similar Indication, Sobi shall pay Apellis [\*\*] Dollars (\$[\*\*]).
- (d) All payments made by Sobi under this Section 1.1 (collectively, the “**Purchase Price**”) shall be made by wire transfer in immediately available funds to the bank account designated in writing by Apellis without any reduction or withholding therefrom. The provisions of Section 9.8 of the CLA shall apply to any payment under this Section 1.1 that is not paid on or before the date such payment is due.

## 1.2 **Modifications to Sobi’s Royalty Obligations.**

- (a) In consideration for Sobi’s payment of the Purchase Price, solely with respect to aggregate Net Sales of Products in the Sobi Territory during the period beginning on July 1, 2025 and ending on the earliest date on which the Bought-Out Royalty Amount *plus* any Hard Cap Buyout Payment made by Apellis pursuant to Section 1.2(c) below *equals* the Hard Cap (the “**Hard Cap Achievement Date**”), the royalties that Sobi is required to pay to Apellis pursuant to Section 9.5 of the CLA shall be reduced to ten percent (10%) of the royalties that Sobi would otherwise be obligated to pay to Apellis pursuant to Section 9.5 of the CLA.
- (b) For purposes of this Section 1.2, the following terms have the following meanings:
  - (i) “**Bought-Out Royalty Amount**” means, as measured on any given date on or after the Effective Date and prior to or on the Hard Cap Achievement Date (the applicable “**Measurement Date**”), an amount equal to (A) the royalty payments that would have been payable by Sobi under Section 9.5 of the CLA with respect to aggregate Net Sales of Products in the Sobi Territory during the period beginning on July 1, 2025 and ending on the Measurement Date if the reduction set forth in Section 1.2(a) above had not been applied, *minus* (B) the royalty payments that are payable (including such amounts that have been paid) by Sobi under Section 9.5 of the CLA with respect to aggregate Net Sales of Products in the Sobi Territory during the period beginning on July 1, 2025 and ending on the Measurement Date after applying the reduction set forth in Section 1.2(a) above, in each case ((A) and (B)) taking into account the royalty reductions specified in Section 9.5.3 of the CLA, but excluding any setoffs beyond the royalty reductions specified in Section 9.5.3 of the CLA.
  - (ii) “**Hard Cap**” means:
    - (A) During the period beginning on the July 1, 2025 and ending on [\*\*], an amount equal to the Purchase Price multiplied by 1.45;

- (B) If the Hard Cap Achievement Date has not occurred prior to [\*\*], during the period beginning on [\*\*], and ending on [\*\*], an amount equal to the Purchase Price multiplied by [\*\*]; and
  - (C) If the Hard Cap Achievement Date has not occurred prior to [\*\*], from and after [\*\*], an amount equal to the Purchase Price multiplied by [\*\*].
- (c) At any time on or after [\*\*], Apellis may elect, in its discretion, to pay to Sobi a one-time payment amount of up to [\*\*] dollars (\$[\*\*]) (a “**Hard Cap Buyout Payment**”), which payment amount shall be counted in determining whether the Hard Cap Achievement Date has been reached, as set forth in Section 1.2(a) above.
- (d) From and after the Hard Cap Achievement Date, this Section 1.2 will be of no further force or effect, and the royalties payable by Sobi with respect to aggregate Net Sales of Products in the Sobi Territory after the Hard Cap Achievement Date shall revert to royalties payable under Section 9.5 of the CLA above without regard to this Section 1.2.

**ARTICLE 2**  
**CONDUCT BY APELLIS OF [\*\*] CLINICAL TRIALS**

2.1 [\*\*] **Clinical Trials.** Notwithstanding anything in Section 4.7.2 or Section 4.7.3 of the CLA to the contrary:

- (a) [\*\*] Apellis conducting (directly or indirectly) one or more Clinical Trials of the Product for the treatment of [\*\*] (each such Clinical Trial, an “[\*\*] **Clinical Trial**”) in any or all of the Major Markets.
- (b) [\*\*] Apellis engaging (directly or indirectly) with the key opinion leaders in the Sobi Territory listed on **Exhibit A** to this Agreement [\*\*]. Apellis shall not engage with any key opinion leaders in the Sobi Territory concerning [\*\*].
- (c) If after the Effective Date Apellis [\*\*] engage (directly or indirectly) with key opinion leader(s) in the Sobi Territory not listed on **Exhibit A** to this Agreement, [\*\*].
- (d) On a [\*\*] Clinical Trial-by-[\*\*] Clinical Trial basis, unless and until [\*\*], to the extent (i) it is legally required or (ii) Apellis [\*\*] reasonably determines that it is appropriate, taking into account the benefit to patients and other approved treatment options available to patients, in any country in the Sobi Territory, to continue to provide or make available the Product to patients in such country who participated in such [\*\*] Clinical Trial, Apellis shall, at its sole cost and expense, continue to provide or make available the Product to such patients in such country.
- (e) Apellis will provide [\*\*] reports to the JEC concerning each [\*\*] Clinical Trial for review and discussion at the JEC concerning Development of the Product in each [\*\*] Clinical Trial.

**ARTICLE 3  
MISCELLANEOUS**

3.1 This Agreement, and all claims arising under or in connection therewith, will be governed by and interpreted in accordance with the substantive laws of the State of New York, without regard to conflict of law principles thereof.

3.2 Notices. All notices that are required or permitted hereunder will be in writing and sufficient if delivered by internationally-recognized overnight courier, addressed as follows (with a courtesy copy sent by email, which will not constitute notice):

If to Apellis: Apellis Pharmaceuticals, Inc.  
APL Del Holdings, LLC  
100 5<sup>th</sup> Avenue  
Waltham, MA 02451  
USA  
Attn: David Watson, General Counsel

With a copy to: Apellis Switzerland GmbH  
Zählerweg 10, 6300 Zug  
Switzerland  
Attn: Managing Director

With a copy to: WilmerHale  
60 State Street  
Boston, MA 02109  
USA  
Attn: Steven D. Barrett

If to Sobi: Swedish Orphan Biovitrum AB (publ)  
SE-112 76 Stockholm, Sweden  
Attn: General Counsel

With a copy to: Latham & Watkins LLP  
12670 High Bluff Drive  
San Diego, CA 92130  
Attn: Steve Chinowsky

or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice will be deemed to have been given on the third Business Day after dispatch.

3.3 Each Party represents that such Party has all necessary power and authority to enter into and perform the obligations of this Agreement and that there are no consents or approvals required to be obtained by such Party for such Party to enter into and perform its obligations

under this Agreement that have not been obtained. Except as expressly and specifically modified hereby, all terms and provisions of the CLA are and shall remain in full force and effect, and all references to the CLA in this Agreement shall hereafter refer to the CLA as it may hereafter be further amended or restated.

- 3.4 In the event of any inconsistency or conflict between the terms and provisions of the CLA, on the one hand, and this Agreement, on the other hand, the terms and provisions of this Agreement shall govern and control. Apellis acknowledges and agrees that this Agreement modifies Sobi's royalty obligations under the CLA as set forth in Section 1.2 above.
- 3.5 This Agreement may be executed in counterparts, all of which taken together will be regarded as one and the same instrument. Counterparts may be delivered via electronic mail, including Adobe™ Portable Document Format (PDF) or any electronic signature complying with the U.S. Federal E-SIGN Act of 2000, and any counterpart so delivered will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Agreement.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

**SWEDISH ORPHAN BIOVITRUM AB (PUBL)**

By: /s/ Guido Oelkers

Name: Guido Oelkers

Title: President & CEO

By: /s/ Torbjorn Hallberg

Name: Torbjorn Hallberg

Title: General Counsel

---

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

**APELLIS PHARMACEUTICALS, INC.**

By: /s/ Timothy Sullivan  
Name: Timothy Sullivan  
Title: CFO

**APELLIS INTERNATIONAL GMBH**

By: /s/ Nur Nicholson  
Name: Nur Nicholson  
Title: CTO

**APL DEL HOLDINGS, LLC**

By: /s/ David Watson  
Name: David Watson  
Title: Manager

---

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002**

I, Cedric Francois, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Apellis Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 30, 2025

By: /s/ Cedric Francois  
Cedric Francois  
Chief Executive Officer

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002**

I, Timothy Sullivan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Apellis Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 30, 2025

By: /s/ Timothy Sullivan  
Timothy Sullivan  
Chief Financial Officer and Treasurer

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Apellis Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Cedric Francois, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 30, 2025

By: /s/ Cedric Francois  
Cedric Francois  
President and Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

---

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Apellis Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Timothy Sullivan, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 30, 2025

By: /s/ Timothy Sullivan  
Timothy Sullivan  
Chief Financial Officer and Treasurer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

---

